

1992 INDEX

A

Abdomen

- abscess, and pleural effusion, May, 315-316
- CT scans in unknown primary malignancy, Apr., 228
- examination in cardiac evaluation, June, 379
- surgery, pleural effusion after, May, 316

Abscess

- intra-abdominal, and pleural effusion, May, 315-316
- lung, differentiated from empyema, May, 301
- periurethral, after chronic indwelling catheter, in elderly, Feb., 136

Absorbent pads and garments: for geriatric urinary incontinence, Feb., 120

Acetylcholine in Alzheimer's disease, Jan., 45-46

- cognitive therapy for deficits in (see Cognitive, therapy, experimental, in Alzheimer's disease, for acetylcholine and cholinergic system deficits)

Acid

- base disturbances, July, 562-564
- metabolic, July, 563-564
- respiratory, July, 562-563
- hydrolases in platelet lysosomes, Aug., 598

Acidemia

- metabolic, July, 564
- respiratory, July, 562

Acidosis

- metabolic, July, 564
- respiratory, July, 562

Acquired immunodeficiency syndrome (see AIDS)

Acyclovir in AIDS

- for herpes simplex infection, Oct., 734
- for leukoplakia, oral hairy, Oct., 735

for varicella-zoster virus infection, Oct., 734-735

zidovudine combined with, Oct., 716

Addison's disease: and dementia, Jan., 31

Adenocarcinoma of unknown primary origin, Apr., 252, 254

chemotherapy, Apr., 248

Adenoma: adrenal, and polycythemia, Mar., 186

Adenosine

deaminase in exudative pleural effusions, May, 284

diphosphate-induced platelet aggregation, Aug., 593

Adenovirus infection: in AIDS, Oct., 736

Adolescent: polycythemia vera in, Mar., 170

ADP-induced platelet aggregation, Aug., 593

Adrenal adenoma: and polycythemia, Mar., 186

Advance directives: for Alzheimer's patients, Jan., 36-37

Advocacy: for Alzheimer's patients, Jan., 36-37

Aerobic glycolysis: in multiple organ failure syndrome, Dec., 867-869

Afibrinogenemia: congenital, and platelet aggregation disorder, Aug., 605

Afipia felis infections: in AIDS, Oct., 745

AFP (see α -Fetoprotein)

Age

-associated memory impairment, Jan., 17

myeloid metaplasia and, agnogenic, Mar., 170

thrombocythemia and, essential, Mar., 170

-related changes in urination, Feb., 87-92

Aggregometer, Aug., 592

1992 INDEX

A

Abdomen

- abscess, and pleural effusion, May, 315-316
- CT scans in unknown primary malignancy, Apr., 228
- examination in cardiac evaluation, June, 379
- surgery, pleural effusion after, May, 316

Abscess

- intra-abdominal, and pleural effusion, May, 315-316
- lung, differentiated from empyema, May, 301
- periurethral, after chronic indwelling catheter, in elderly, Feb., 136

Absorbent pads and garments: for geriatric urinary incontinence, Feb., 120

Acetylcholine in Alzheimer's disease, Jan., 45-46

- cognitive therapy for deficits in (see Cognitive, therapy, experimental, in Alzheimer's disease, for acetylcholine and cholinergic system deficits)

Acid

- base disturbances, July, 562-564
- metabolic, July, 563-564
- respiratory, July, 562-563
- hydrolases in platelet lysosomes, Aug., 598

Acidemia

- metabolic, July, 564
- respiratory, July, 562

Acidosis

- metabolic, July, 564
- respiratory, July, 562

Acquired immunodeficiency syndrome (see AIDS)

Acyclovir in AIDS

- for herpes simplex infection, Oct., 734
- for leukoplakia, oral hairy, Oct., 735

for varicella-zoster virus infection, Oct., 734-735

zidovudine combined with, Oct., 716

Addison's disease: and dementia, Jan., 31

Adenocarcinoma of unknown primary origin, Apr., 252, 254

chemotherapy, Apr., 248

Adenoma: adrenal, and polycythemia, Mar., 186

Adenosine

deaminase in exudative pleural effusions, May, 284

diphosphate-induced platelet aggregation, Aug., 593

Adenovirus infection: in AIDS, Oct., 736

Adolescent: polycythemia vera in, Mar., 170

ADP-induced platelet aggregation, Aug., 593

Adrenal adenoma: and polycythemia, Mar., 186

Advance directives: for Alzheimer's patients, Jan., 36-37

Advocacy: for Alzheimer's patients, Jan., 36-37

Aerobic glycolysis: in multiple organ failure syndrome, Dec., 867-869

Afibrinogenemia: congenital, and platelet aggregation disorder, Aug., 605

Afipia felis infections: in AIDS, Oct., 745

AFP (see α -Fetoprotein)

Age

-associated memory impairment, Jan., 17

myeloid metaplasia and, agnogenic, Mar., 170

thrombocythemia and, essential, Mar., 170

-related changes in urination, Feb., 87-92

Aggregometer, Aug., 592

- Aggressiveness: in Alzheimer's disease, management, Jan., 38-39
- Agnogenic myeloid metaplasia: and age, Mar., 170
- AIDS, Sept., 646-690; Oct., 705-764 (See also HIV)
- bacterial infections in, Oct., 744-745
- candidiasis in, Oct., 740-741
- chemotherapy in, antiviral, Oct., 705-716
- guidelines, Oct., 717-719
- cryptococcosis in, Oct., 741-743
- cryptosporidiosis in, Oct., 728-729
- cytomegalovirus infection in, Oct., 730-733
- diagnosis, Sept., 669-672
- didanosine in (see Didanosine in AIDS)
- dideoxycytidine in (see Dideoxycytidine in AIDS)
- epidemiology, worldwide, Sept., 667-669
- Epstein-Barr virus infection in, Oct., 735
- fungal infections in, Oct., 740-744
- herpes simplex virus infection in, Oct., 733-734
- immunomodulators in, Oct., 720
- infections, malignancies, and neurologic syndromes associated with, Sept., 657
- infectious complications, Oct., 720-745
- isoproporiasis in, Oct., 729-730
- Kaposi's sarcoma in, Oct., 746-748
- pleural effusions and, May, 311
- lymphoma in, non-Hodgkin's, Oct., 748-749
- mycobacterial infections in, Oct., 736-740
- Mycobacterium avium* complex disease in, Oct., 736-738
- Mycobacterium tuberculosis* infection in, Oct., 738-739
- natural history, Sept., 653, 655-658
- neoplastic complications, Oct., 720-721, 746-750
- opportunistic infections in, treatment regimens, Oct., 724-725
- pathogenesis, Sept. 652-655
- pleural effusions in, May, 311
- Pneumocystis carinii* disease in, Oct., 721-726
- protozoan infections in, Oct., 721-730
- reverse transcriptase inhibitors in, Oct., 715-716
- therapy, Oct., 705-720
- combination, Oct., 716
- toxoplasmosis in, Oct., 726-728
- vaccines in, Oct., 720
- varicella-zoster virus infection in, Oct., 734-735
- viral infections in, Oct., 730-736
- zidovudine in (see Zidovudine in AIDS)
- Air distribution: effect of localized airway obstruction on, July, 546
- Airflow
- limitation
- compliance in, effect of respiratory frequency increase on, July, 548
- static volume-pressure curve in, July, 525
- resistance (see Flow resistance)
- volume relationship during forced vital capacity maneuver, July, 537
- Airway
- conductance, relationship to lung volume, July, 536
- obstruction, localized
- effect on air distribution, July, 546
- effect on volume-pressure relationship, July, 547
- peripheral, flow resistance in, July, 543
- resistance
- (See also Flow resistance)
- effect of inhaled methacholine or histamine on, July, 550

Airway (cont.)

- relationship between lung volume and, July, 536
- responsiveness tests, July, 548-551
- Albinism: platelet granule deficiency in, Aug., 608
- Albumin excretion: urinary, effect of enalapril or metoprolol in diabetic nephropathy on, Nov., 824
- Alcohol: and hypertension, Nov., 803
- Alkalemia
 - metabolic, July, 564
 - respiratory, July, 563
- Alkaline phosphatase: leukocyte, in polycythemia vera, Mar., 177, 178
- Alkalosis
 - metabolic, July, 564
 - respiratory, July, 563
- Alkylating agents: in polycythemia vera, Mar., 195
- Allopurinol: for gout in polycythemia vera, Mar., 197
- Alpha-adrenergic blocker in geriatric urinary incontinence overflow, Feb., 131
- stress, Feb., 130
- Alpha-fetoprotein (*see* α -Fetoprotein)
- Altitude: high, and polycythemia, Mar., 185
- Aluminum exposure: and Alzheimer's disease, Jan., 15
- Alveolar
 - hypoventilation and polycythemia, Mar., 185
 - ventilation, July, 553-555
- Alzheimer's disease, Jan., 13-64
 - acetylcholine in, Jan., 45-46
 - therapy targeted toward (*see* Cognitive, therapy, experimental, in Alzheimer's disease, for acetylcholine and cholinergic system deficits)
 - advance directives and, Jan., 36-37
 - advocacy and, Jan., 36-37

- aggressiveness in, management, Jan., 38-39
- anatomy
 - neurochemical, Jan., 45-47
 - pathologic, macroscopic, Jan., 40
 - pathologic, microscopic, Jan., 40-45
- ancillary tests in, Jan., 23-26
- clinical evaluation for, Jan., 16-26
- community resources, Jan., 35-36
- course, Jan., 18-21
- criteria for, NINCDS-ADRDA, Jan., 18
- day care for, Jan., 35
- defining, Jan., 18
- depression in, management, Jan., 38
- driving and, Jan., 37
- drugs in, Jan., 49
- epidemiology, Jan., 13-16
- genetics of, Jan., 26-27
- guardianship and, Jan., 37
- hospice care in, Jan., 36
- management
 - behavioral, Jan., 37-39
 - medical, Jan., 34-39
- neuritic plaques in, Jan., 41-43
- neurofibrillary tangles in, Jan., 43-44
- neurologic examination in, Jan., 22-23
- neuropsychological performance testing in, Jan., 22
- neurotransmitters in, aminergic, Jan., 46
 - cognitive therapy directed toward, Jan., 29
- nootropics in, Jan., 49
- nursing home special care units for, Jan., 36
- pathology, Jan., 39-45
- power of attorney and, Jan., 37
- presentation, Jan., 18-21
- prevalence, Jan., 14
 - estimated, in U.S. by year 2050, Jan., 15
- public health impact, Jan., 13-16
- radiology in (*see* Radiology, in Alzheimer's disease)

- respite care in, Jan., 35-36
 sleep/wake disturbances in, management, Jan., 38
 somatostatin in, Jan., 46-47
 therapy
 cognitive, experimental (see Cognitive, therapy, experimental, in Alzheimer's disease)
 noncognitive, Jan., 35-37
 Amebiasis: pleural, May, 309
 Amiloride: in hypertension, in elderly, Nov., 822
 Aminergic neurotransmitters in Alzheimer's disease, Jan., 46
 cognitive therapy directed toward, Jan., 49
 Amiodarone: causing pleural effusion, May, 319
 Amphotericin B
 in aspergillosis
 in AIDS, Oct., 744
 pleural, May, 307
 in blastomycosis, pleural, May, 307
 in coccidioidomycosis
 in AIDS, Oct., 744
 pleural, May, 308
 in cryptococcosis
 in AIDS, Oct., 742-743
 pleural, May, 308
 in histoplasmosis in AIDS, Oct., 743
 Amylase: pleural fluid, in exudative pleural effusions, May, 282-283
 Amyloid
 cerebrovascular, in Alzheimer's disease, Jan., 43
 precursor protein in Alzheimer's disease, Jan., 43
 Amyloidosis: cardiac, endomyocardial biopsy in, June, 488
 Anabolic steroids: for anemia in postpolycythemic myeloid metaplasia, Mar., 202
 Anagrelide: in polycythemia vera, Mar., 191
 Androgens: and polycythemia, Mar., 186
 Anemia
 in myeloid metaplasia, postpolycythemic
 chemotherapy for, Mar., 202
 erythropoietin in, recombinant, Mar., 202
 splenectomy for, Mar., 203
 splenectomy for, acute leukemia after, Mar., 201
 steroids in, anabolic, Mar., 202
 therapy, Mar., 201-203
 zidovudine-induced, Oct., 709-710
 Angina
 as end point of exercise testing, June, 413
 new-onset, thallium imaging in, June, 462
 Angiocardiogram: equilibrium radionuclide, June, 456-457
 Angioendotheliomatosis: and dementia, Jan., 32
 Angiogenesis, Apr., 225
 Angiography: coronary, interpretation, June, 469-470
 Angiotensin-converting enzyme inhibitors: in hypertension in diabetics, Nov., 823-824
 Anomaly
 Ebstein's, echocardiography in, June, 439
 May-Hegglin, Aug., 602
 Antibiotics: beta lactam, causing platelet dysfunction, Aug., 612
 Antibody
 antinuclear, pleural fluid, measurement in lupus pleuritis, May, 318
 antiplatelet, and acquired platelet disorders, Aug., 616-617
 monoclonal, in multiple organ failure syndrome therapy, Dec., 884-885
 Anticoagulants: causing platelet dysfunction, Aug., 612-613
 Antidepressants
 in Alzheimer's disease, Jan., 38
 platelet dysfunction due to, Aug., 613

- Antifibrinolytic agents: for platelet function disorders, Aug., 622
- Antigen
- carcinoembryonic, in unknown primary malignancy, Apr., 231
 - challenge, effect on airway resistance in antigen-induced asthma, July, 550
 - HIV, in HIV diagnosis, Sept., 675-676
 - prostate-specific
 - immunocytochemical stain for, Apr., 237
 - in malignancy of unknown primary origin, Apr., 232
 - specific response system in multiple organ failure syndrome, Dec., 877
- Antihistamines: causing platelet dysfunction, Aug., 613
- Antihypertensive drugs (*see* Drug, therapy in hypertension)
- Antiinflammatory agents, nonsteroidal
- hemorrhage in polycythemia vera due to, Mar., 172
 - platelet dysfunction due to, Aug., 611
- Antinuclear antibody: pleural fluid, measurement in lupus pleuritis, May, 318
- Antiplatelet antibodies: and acquired platelet disorders, Aug., 616-617
- Antipsychotics: causing platelet dysfunction, Aug., 613
- Antithrombotics: causing platelet dysfunction, Aug., 612-613
- Antiviral chemotherapy in AIDS, Oct., 705-716
- guidelines, Oct., 717-719
- Aortic
- coarctation on chest radiography, June, 407-409
 - disease, MRI in, June, 465
 - dissections, transesophageal echocardiography in, June, 427
 - regurgitation, June, 481-483
 - cardiac catheterization in, June, 481-482
 - cardiac catheterization in, for prognosis assessment, June, 482-483
 - echocardiography in, June, 437, 438
 - hemodynamic assessment, June, 482
 - stenosis (*see* Stenosis, aortic)
 - valve, bicuspid, echocardiography of, June, 454
- Aphasia: progressive, and dementia, Jan., 33
- Apical impulse: left ventricular, June, 368
- Apnea: sleep, and drug therapy in hypertension, Nov., 824-825
- Apoplexy: pulmonary, June, 361
- Apoptosis, Dec., 877
- Aprotinin: in cardiac bypass surgery, Aug., 616
- Arginine: in multiple organ failure syndrome, Dec., 885
- Arrhythmias
- in cor pulmonale, June, 392
 - exercise-induced, June, 415
- Artery(ies)
- coronary (*see* Bypass, coronary artery)
 - hypoxemia, causing polycythemia, Mar., 185
 - pressures in cardiac evaluation, June, 365-368
 - pulse (*see* Pulse, arterial)
- Arthritis: rheumatoid, pleural effusion in, May, 317
- Arthropods: HIV transmission by, Sept., 665
- Artificial insemination: HIV transmission by, Sept., 664
- Asbestos exposure: causing pleural effusion, May, 320
- Ascites, cirrhosis, and pleural effusion (*see* Hydrothorax, hepatic)
- A68: in Alzheimer's disease, Jan., 44
- Aspergillosis
- in AIDS, Oct., 744
 - pleural, May, 307

Aspirin

- /dipyridamole in polycythemia vera, Mar., 191
- effect on platelet aggregation, Aug., 594
- platelet dysfunction due to, Aug., 609-611

Asthma

- airway resistance in, effect of inhaled methacholine or histamine on, July, 550
- antigen-induced, effect of antigen challenge on airway resistance in, July, 550
- dyspnea in, June, 357-358
- flow resistance in, July, 534
- pulsus paradoxus in, June, 368

Atherosclerotic complications: in polycythemia vera, Mar., 171

Atrial

enlargement

- ECG in (see Electrocardiogram, in atrial enlargement)
- echocardiography, June, 450
- on radiography, chest, June, 401-403
- septal defect (see Septal defect, atrial)
- tachycardia, multifocal, in cor pulmonale, June, 392
- thrombi, echocardiography in, June, 452-453
- transesophageal, June, 427-428

Auscultation, cardiac, June, 369-372

- dynamic, June, 377-378
- during handgrip, June, 378
- after premature ventricular contraction beats, June, 378
- during squatting, June, 377
- during Valsalva, June, 377

3'-Azido-2',3'-dideoxythymidine (see Zidovudine)

Azithromycin in AIDS

- for cryptosporidiosis, Oct., 729
- for *Mycobacterium avium* complex disease, Oct., 738
- for toxoplasmosis, Oct., 728

Azotemia: prerenal, after resuscitation, Dec., 872

AZT (see Zidovudine)

B

Bacterial infections

- in AIDS, Oct., 744-745
- of pleural space (see Parapneumonic effusions and bacterial infections of pleural space)

Bacteriologic stains: in exudative pleural effusions, May, 283

Bacteriology: of parapneumonic effusions, May, 299-300

- Bacteriuria, in elderly, Feb., 90-91
- pyuria and, in men, Feb., 106
- treatment, Feb., 91-92

Barium enema: in unknown primary malignancy, Apr., 229

B cells: in HIV infection, Sept., 672

Beats: premature ventricular contraction, auscultation after, June, 378

Behavioral

- disturbances in Alzheimer's disease, Jan., 20
- management of Alzheimer's disease, Jan., 37-39
- therapies in geriatric urinary incontinence, Feb., 120-127
- caregiver-dependent, Feb., 124-127
- caregiver-dependent, examples, Feb., 124
- patient-dependent, Feb., 121-124
- patient-dependent, examples, Feb., 122
- training in geriatric urinary incontinence, Feb., 121-123

Bernard-Soulier syndrome, Aug., 600-602

Beta-blockers in hypertension in elderly, Nov., 812-813, 822 as initial therapy, Nov., 814, 815

Beta lactam antibiotics: causing platelet dysfunction, Aug., 612

Bethanechol

- in Alzheimer's disease, Jan., 48
- in incontinence, geriatric overflow urinary, Feb., 131

BHAP compounds: in AIDS, Oct., 716

- Bicuspid aortic valve: echocardiography, June, 454
- Biofeedback: for geriatric urinary incontinence, Feb., 121
- Biologic principles: in unknown primary malignancy, Apr., 245-246
- Biopsy**
- bone marrow, in postpolycythemic myeloid metaplasia, Mar., 200
 - endomyocardial, June, 487-490
 - gastric, and aspirin and platelet dysfunction, Aug., 611
 - pleural
 - needle, in mesothelioma, malignant, May, 297
 - needle, in pleural effusions, exudative, May, 285-286
 - needle, in pleural effusions, malignant, May, 293
 - open, in exudative pleural effusions, May, 287
- Bioptome: Stanford, in endomyocardial biopsy, June, 488-489
- BIRG-587: in AIDS, Oct., 715-716
- Bisferiens pulse, June, 367
- Bisheteroaryl piperazine compounds: in AIDS, Oct., 715-716
- Bladder**
- carcinoma, laboratory studies in, Feb., 106
 - contractility impairment with detrusor hyperactivity causing incontinence, in elderly, Feb., 98-99
 - function changes, age-related, Feb., 87-88
 - records in evaluation of geriatric urinary incontinence, Feb., 102-103
 - in ambulatory clinic settings, Feb., 104
 - in institutional settings, Feb., 105
 - relaxants in geriatric incontinence, Feb., 130
 - retraining in geriatric incontinence, Feb., 121-124
- Blastomycosis: pleural, May, 307
- Bleomycin: in malignant pleural effusions, May, 294, 295
- Blessed Orientation, Memory Concentration Test: in Alzheimer's disease, Jan., 22
- Blood**
- carbon dioxide transport in, July, 561
 - cells
 - red (*see* Red cell)
 - white (*see* Leukocyte)
 - chemistries, effects of diuretic dosage on, Nov., 815
 - flow
 - cerebral, in polycythemia vera, Mar., 171
 - in lung, upright, July, 556
 - gas transport in, July, 559-564
 - oxygen transport in, July, 560-561
 - pressure
 - effects of diuretic dosage on, Nov., 815
 - effects of enalapril or metoprolol in diabetic nephropathy on, Nov., 824
 - measurement in cardiac evaluation, June, 365-366
 - measurement technique recommended by British Hypertension Society, Nov., 785
 - monitoring, Nov., 784-788
 - monitoring, ambulatory, Nov., 787-788
 - monitoring, out-of-the-office, Nov., 784-786
 - monitoring, out-of-the-office, during therapy, Nov., 786-787
 - monitoring, during therapy, Nov., 786-787
 - relation to risk of cardiovascular disease, Nov., 827
 - response during exercise testing, abnormal, June, 414
 - products, HIV transmission by, Sept., 663-664
- Body**
- composition alteration in multiple organ failure syndrome, Dec., 866-867

- mass, lean, after resuscitation, Dec., 867
- plethysmograph, measurement of airway resistance in, July, 535
- Bone**
- marrow
- biopsy in postpolycythemic myeloid metaplasia, Mar., 200
 - cytogenetics in polycythemia vera, Mar., 182
 - location in polycythemia vera, Mar., 179-181
 - morphology in polycythemia vera, Mar., 181
 - in polycythemia vera, MRI of, Mar., 180
 - transplant in Glanzmann's thrombasthenia, in children, Aug., 605
 - scans in unknown primary malignancy, Apr., 230
- Breast**
- cancer (see Cancer, breast)
 - feeding and HIV transmission, Sept., 663
- Breath sounds, June, 378-379
- Breathing: control of, July, 564-565
- Bromocriptine: causing pleural effusion, May, 319
- Bronchial vein varices: causing hemoptysis in mitral stenosis, June, 361
- Bronchitis: winter, causing hemoptysis in mitral stenosis, June, 362
- Bronchoalveolar lavage: in diagnosis of *Pneumocystis carinii* pneumonia in AIDS, Oct., 722
- Bronchodilators: effect on ventilatory pattern in obstructive disease, July, 540, 541, 542
- Bronchoscopy: in exudative pleural effusions, May, 286
- Bruce exercise test protocol: standard, June, 415-416
- Budd-Chiari syndrome: and polycythemia vera, Mar., 171
- Busulfan**
- in myeloproliferative disorders, Aug., 618
 - in polycythemia vera, Mar., 196
- Bypass**
- cardiac
- DDAVP in, Aug., 621
 - platelet dysfunction due to, Aug., 615-616
- coronary artery
- aspirin and platelet dysfunction, Aug., 611
 - pleural effusion after, May, 321
- C**
- CA**
- 15-3 in unknown primary malignancy, Apr., 233-235
 - 19-9 in unknown primary malignancy, Apr., 234
 - 125 in unknown primary malignancy, Apr., 233
- Caffeine: and coffee, Nov., 808-809
- Calcium**
- channel blockers
- in hypertension, in diabetics, Nov., 823-824
 - in hypertension; in elderly, Nov., 822
 - in incontinence, urge, in elderly, Feb., 127-130
 - platelet dysfunction due to, Aug., 613
 - supplements in hypertension, Nov., 806
- Campylobacter* infections: in AIDS, Oct., 744
- Cancer**
- breast
- CA 125 in, Apr., 233-234
 - cytogenetic analysis, Apr., 241
 - epidermal growth factor in, Apr., 246
- colon, cytogenetic analysis, Apr., 241
- colorectal, CA 19-9 in, Apr., 234
- gastric, CA 19-9 in, Apr., 234
- hepatobiliary, CA 19-9 in, Apr., 234
- invasive, transition to, Apr., 225
- ovarian, CA 125 in, Apr., 233
- pancreas, CA 19-9 in, Apr., 234

Cancer (*cont.*)

- prostate
 - disseminated, Apr., 252
 - immunocytochemical stain for prostate-specific antigen in, Apr., 237
- Candidiasis: in AIDS, Oct., 740-741
- Captopril challenge test: for renovascular hypertension, Nov., 821
- Carbamazepine: in Alzheimer's disease, Jan., 39
- Carbenicillin-induced platelet dysfunction, Aug., 612
- Carbon dioxide
 - respiratory response to, July, 564-565
 - tension, pleural fluid, in exudative pleural effusions, May, 284
 - transport in blood, July, 561
- Carboxyhemoglobin: and polycythemia, Mar., 185-186
- Carcinoembryonic antigen: in unknown primary malignancy, Apr., 231
- Carcinoma
 - adenocarcinoma of unknown primary origin, Apr., 252, 254
 - chemotherapy, Apr., 248
 - bladder, laboratory studies in, Feb., 106
 - neuroendocrine, poorly differentiated, Apr., 251-252
 - squamous cell, of unknown primary origin, Apr., 249
- Cardiac (*see* Heart)
- Cardiology, nuclear, June, 455-463
 - first-pass studies, June, 457-458
 - exercise, June, 458
 - of right ventricular function, June, 458-459
 - imaging principles, June, 456
 - techniques for assessing cardiac function, June, 456-459
- Cardiomyopathy
 - dilated
 - echocardiography of left ventricular systolic function in, June, 443-444

- endomyocardial biopsy in, June, 487-488
- hypertrophic, endomyocardial biopsy in, June, 487-488
- restrictive, cardiac catheterization in, June, 483-486
- Cardiorespiratory adaptation to exercise, July, 566-571
 - poor cooperation and, July, 571
- Cardiotoxicity: doxorubicin, endomyocardial biopsy in, June, 488
- Cardiovascular
 - disease risk related to blood pressure, Nov., 827
 - limitation during exercise, July, 569-570
- Care
 - day, for Alzheimer's patients, Jan., 35
 - hospice, in Alzheimer's disease, Jan., 36
 - respite, in Alzheimer's disease, Jan., 35-36
 - supportive, for platelet function disorders, Aug., 619
- Catabolic rate: after resuscitation, Dec., 871
- Catabolism: total body protein, after resuscitation, Dec., 871-872
- Catheter in geriatric urinary incontinence, Feb., 134-138
 - external, Feb., 134
 - in dwelling, chronic, Feb., 135-138
- Catheterization
 - cardiac, June, 465-490
 - in aortic regurgitation, June, 481-482
 - in aortic regurgitation, for prognosis assessment, June, 482-483
 - in aortic stenosis, June, 473-476
 - in cardiomyopathy, restrictive, June, 483-486
 - indications, June, 465-466
 - in mitral regurgitation, June, 477-479

in mitral regurgitation, for prognosis assessment, June, 479-481
 in mitral stenosis, June, 470-473
 in myocardial disease, June, 483-487
 in pericardial disease, June, 483-487
 in pericarditis, constrictive, June, 483-486
 in tamponade, cardiac, June, 486-487, 488, 489
 techniques, June, 466-467
 in tricuspid regurgitation, June, 481
 in tricuspid stenosis, June, 473
 in valvular heart disease, June, 470-483
 intermittent, in geriatric urinary incontinence, Feb., 135
 Cat scratch disease: in AIDS, Sept., 671; Oct., 745
 CEA: in unknown primary malignancy, Apr., 231
 Cell
 B, in HIV infection, Sept., 672
 blood (see Blood, cells)
 endothelial, in multiple organ failure syndrome, Dec., 875-876
 germ cell tumor (see Germ cell tumor)
 hairy cell leukemia, platelet dysfunction in, Aug., 618
 killer, lymphokine-activated, in metastatic melanoma, Apr., 245
 Central nervous system lymphoma: in AIDS, Oct., 748-749
 CERAD neuropsychological testing: in Alzheimer's disease, Jan., 22
 Cerebellar hemangiomas: and polycythemia, Mar., 186
 Cerebral blood flow: in polycythemia vera, Mar., 171
 Cerebrospinal fluid abnormalities: in HIV infection, Sept., 672

Cerebrovascular amyloid: in Alzheimer's disease, Jan., 43
 Cervical papillomavirus infection: and HIV, Sept., 671
 Chamber, heart (see Heart, chamber)
 Chédiak-Higashi syndrome: dense granule deficiency in, Aug., 608
 Chemotherapy
 of adenocarcinoma of unknown primary origin, Apr., 248
 agents causing platelet dysfunction, Aug., 613
 antiviral, in AIDS, Oct., 705-716
 guidelines, Oct., 717-719
 of germ cell tumors, gonadal and extragonadal, Apr., 251
 of Kaposi's sarcoma in AIDS, Oct., 747, 748
 of lymphoma, large-cell, Apr., 250-251
 of malignancy of unknown origin, Apr., 248-249
 of mesothelioma, peritoneal, Apr., 253
 of myeloid metaplasia, postpolycythemic, Mar., 202
 Chest
 CT scans in unknown primary malignancy, Apr., 228-229
 examination in cardiac evaluation, June, 378-379
 pain in cardiac evaluation, June, 358-359
 radiography (see Radiography, chest)
 tubes
 in parapneumonic effusions (see Parapneumonic effusions and bacterial infections of pleural space, chest tube drainage in)
 in pleural effusions after Fontan procedure, May, 291
 Children
 AIDS in, zidovudine in, Oct., 707
 DDAVP in, Aug., 621
 myelodysplasia with Bernard-Soulier-like platelets in, Aug., 602

Children (cont.)

- newborn, polymerase chain reaction for HIV infection in, Sept., 679
- polycythemia vera in, Mar., 170
- thrombasthenia in, Glanzmann's, bone marrow transplantation in, Aug., 605
- Chinese black tree fungus: causing platelet dysfunction, Aug., 613
- Chlorambucil: in polycythemia vera, Mar., 195
- Chlorthalidone: in hypertension, in elderly, Nov., 822
- Cholangitis: sclerosing, with papillary stenosis due to cytomegalovirus in AIDS, Oct., 731
- Cholecystitis: cryptosporidial, in AIDS, Oct., 729
- Cholesterol: pleural fluid, in exudative pleural effusions, May, 284
- Cholestyramine: for pruritus in polycythemia vera, Mar., 196
- Choline acetyltransferase activity deficits: in Alzheimer's disease, Jan., 45
- Cholinergic system (see Cognitive, therapy, experimental, in Alzheimer's disease, for acetylcholine and cholinergic system deficits)
- Chorionic gonadotropin: human, in unknown primary malignancy, Apr., 232
- Chorioretinitis: cytomegalovirus, in AIDS, Oct., 731
- Chromosome abnormalities in Alzheimer's disease, Jan., 26-27
 - clonal, in marrow cells in polycythemia vera, Mar., 182
 - in solid malignant neoplasms, Apr., 242
- Churg-Strauss syndrome: causing pleural disease, May, 318
- Cigarette smoking (see Smoking)
- Cimetidine: for pruritus in polycythemia vera, Mar., 196

Cirrhosis

- ascites and pleural effusion (see Hydrothorax, hepatic)
- polycythemia and, Mar., 185
- Clamps: for geriatric urinary incontinence, Feb., 132-133
- Clarithromycin in AIDS
 - for cryptosporidiosis, Oct., 729
 - for *Mycobacterium avium* complex disease, Oct., 738
 - for toxoplasmosis, Oct., 728
- Clindamycin
 - primaquine in *Pneumocystis carinii* disease in AIDS, Oct., 722, 723
 - in toxoplasmosis in AIDS, Oct., 727
- Closing capacity, July, 548
- Closing volume, July, 548
- Clot retraction, Aug., 599
- Clubbing: in cardiac evaluation, June, 380
- CNS lymphoma: in AIDS, Oct., 748-749
- CO₂ (see Carbon dioxide)
- Coagulation
 - disseminated intravascular, platelet dysfunction in, Aug., 618
 - in polycythemia vera, Mar., 178-179
- Coarctation of aorta: on chest radiography, June, 407-409
- Cobalamin deficiency: and dementia, Jan., 31
- Coccidioidomycosis in AIDS, Oct., 744
- pleural, May, 307-308
- Coffee: and hypertension, Nov., 808-809
- Cognitive
 - assessment in Alzheimer's disease, Jan., 17
 - therapy, experimental, in Alzheimer's disease, for acetylcholine and cholinergic system deficits, Jan., 47-49
 - decreased degradation, Jan., 48
 - direct antagonists, Jan., 48
 - future directions, Jan., 48-49
 - increased release, Jan., 47

- precursor loading, Jan., 47
therapy, experimental, in Alzheimer's disease, for aminergic system deficits, Jan., 49
- Colchicine: in pleural disease due to familial Mediterranean fever, May, 319
- Collagen
-induced platelet aggregation, Aug., 593
receptor on platelets, Aug., 591
vascular diseases causing pleural disease, May, 317-319
- Colon cancer: cytogenetic analysis, Apr., 241
- Colorectal cancer: CA 19-9 in, Apr., 234
- Color-flow Doppler echocardiography, June, 429-430
- Community resources: for Alzheimer's disease, Jan., 35-36
- Compliance (see Lung, compliance)
- Computed tomography (see Tomography, computed)
- Confusional episode: acute, in elderly medical patients, Jan., 20
- Continence, urinary
dependency, Feb., 99
medications affecting, Feb., 96
requirements for, Feb., 92-93
- Contrast agents: radiographic, causing platelet dysfunction, Aug., 613
- Cori cycle: in multiple organ failure syndrome, Dec., 869
- Coronary
angiography, interpretation, June, 469-470
artery bypass (see Bypass, coronary artery)
heart disease (see Heart, disease, coronary)
- Cor pulmonale
arrhythmias in, June, 392
atrial tachycardia in, multifocal, June, 392
ECG in (see Electrocardiogram, in cor pulmonale)
- Corrigan's pulse, June, 367
- Corticosteroids
in platelet function disorders, Aug., 621
in platelet secretion disorders, Aug., 606
in pleural disease due to immunoblastic lymphadenopathy, May, 319
in pleural effusions, sarcoid, May, 323
in *Pneumocystis carinii* disease in AIDS, Oct., 722
- Corynebacterium parvum*: in malignant pleural effusions, May, 295
- Cost
of bleomycin in malignant pleural effusions, May, 295
of drug therapy in hypertension, Nov., 825-826
-effectiveness of prompted voiding for geriatric urinary incontinence, Feb., 125
of laboratory tests in pleural effusions, May, 279-280
of urinary incontinence, geriatric, Feb., 83
- Cough: in cardiac evaluation, June, 362
- Crackles: in cardiac evaluation, June, 378-379
- Creutzfeldt-Jakob disease, Jan., 34
- Cryoprecipitate: in uremic patients, Aug., 615
- Cryptococcosis
in AIDS, Oct., 741-743
pleural, May, 308
- Cryptosporidiosis: in AIDS, Oct., 728-729
- CT (see Tomography, computed)
- Culture
in pleural effusions, exudative, May, 283
viral, in HIV diagnosis, Sept., 677-678
- Cushing's disease: and dementia, Jan., 31
- Cyanosis: ruddy, in polycythemia vera, Mar., 173

Cyclophosphamide: in polycythemia vera, Mar., 195
 Cyproheptadine: for pruritus in polycythemia vera, Mar., 196
 Cyst: renal, and polycythemia, Mar., 186
 Cystocele
 grading system, Feb., 107
 incontinence and, geriatric, Feb., 106
 Cystometrogram
 filling, Feb., 116
 voiding, Feb., 116
 Cystometry: simple, procedure for, Feb., 111
 Cystourethroscopy: in geriatric urinary incontinence, Feb., 113
 Cytogenetics
 bone marrow, in polycythemia vera, Mar., 182
 of malignancy of unknown origin, Apr., 241-242
 Cytokine effects: of multiple organ failure syndrome, Dec., 866
 Cytology, pleural fluid, in pleural effusions
 exudative, May, 282
 malignant, May, 293
 Cytomegalovirus infection: in AIDS, Oct., 730-733
 Cytotoxic therapy: in pleural disease due to immunoblastic lymphadenopathy, May, 319

D

Dantrolene: causing pleural effusion, May, 319
 Dapsone in *Pneumocystis carinii* disease in AIDS
 prophylactic, Oct., 726
 trimethoprim combined with, Oct., 722, 723
 Daunorubicin: causing platelet dysfunction, Aug., 613
 Day care: for Alzheimer's patients, Jan., 35
 DDAVP
 in Bernard-Soulier syndrome, Aug., 602
 in gray platelet syndrome, Aug., 607
 in platelet function disorders, Aug., 620-621
 in platelet granule deficiency, dense, Aug., 608
 in platelet secretion disorders, Aug., 606
 in uremic patients, Aug., 615
 ddC (see Dideoxycytidine)
 ddl (see Didanosine)
 Dead space
 effect on alveolar ventilation, July, 554
 -like ventilation, July, 558
 Death
 Alzheimer's disease and, Jan., 21
 from coronary heart disease related to cholesterol, blood pressure, and smoking, Nov., 789
 in hypertension related to left ventricular hypertrophy, Nov., 793
 Decortication
 in paragonimiasis, pleural, May, 310
 in parapneumonic effusions, May, 303-304
 in pleural histoplasmosis, May, 309
 Delirium: differentiated from dementia, Jan., 28
 Dementia
 adult, differential diagnosis, Jan., 27-34
 Alzheimer's (see Alzheimer's disease)
 aphasia and, progressive, Jan., 33
 cobalamin deficiency and, Jan., 31
 criteria for, NINCDS-ADRDA, Jan., 17-18
 defining, Jan., 16-18
 degenerative, Jan., 32-34
 diagnostic evaluation, Jan., 24
 drug toxicity causing, Jan., 27-28
 endocrinopathies and, Jan., 31-32
 frontal lobe, Jan., 33

- HIV
 after didanosine, Oct., 712
 after zidovudine, Oct., 709
 in Huntington's disease, Jan., 33-34
 hydrocephalic, symptomatic, Jan., 30
 in Korsakoff's syndrome, Jan., 30-31
 multi-infarct, Jan., 29
 in Parkinson's disease, Jan., 32-33
 in Pick's disease, Jan., 33
 potentially treatable, Jan., 27-32
 recognizing, Jan., 16-18
 vascular, Jan., 29-30
 vasculitis and, Jan., 32
 Dementing conditions: potentially treatable, Jan., 31-32
 Demographic data: for multiple organ failure syndrome, Dec., 860
 Dental
 extraction, DDAVP and gray platelet syndrome, Aug., 607
 procedures, antifibrinolytics after, Aug., 622
 Deoxydidehydrothymidine: in AIDS, Oct., 715
 L-Deprenyl: in depression in Alzheimer's disease, Jan., 38
 Depression in Alzheimer's disease, Jan., 21
 management, Jan., 38
 Dermatologic manifestations: of HIV infection, Sept., 671
 Desmopressin acetate (see DDAVP)
 Detrusor
 hyperactivity with impaired bladder contractility causing incontinence, in elderly, Feb., 98-99
 hyperreflexia causing urge incontinence, in elderly, Feb., 98
 instability causing urge incontinence, in elderly, Feb., 98
 d4T: in AIDS, Oct., 715
 Diabetes mellitus
 drug therapy in hypertension and, Nov., 822-824
 nephropathy in, enalapril or metoprolol in, Nov., 824
 Dialysis
 effect on bleeding tendency in uremic patients, Aug., 615
 hemodialysis in multiple organ failure syndrome, Dec., 860
 peritoneal, and pleural effusions, May, 290
 pleural effusions and, May, 322
 Diapers: adult, for geriatric urinary incontinence, Feb., 120
 Diaphragmatic hernia: and pleural effusion, May, 316
 Diastolic function: echocardiography of, June, 446-447
 Diclazuril: in cryptosporidiosis in AIDS, Oct., 729
 Didanosine in AIDS, Oct., 711-714
 clinical experience, Oct., 712-713
 mechanism of action, Oct., 711
 pharmacology, Oct., 711-712
 resistance, Oct., 713-714
 toxicity, Oct., 713
 Dideoxycytidine in AIDS, Oct., 714-715
 clinical experience, Oct., 714-715
 mechanism of action, Oct., 714
 pharmacology, Oct., 714
 resistance, Oct., 715
 toxicity, Oct., 715
 2',3'-Dideoxyinosine (see Didanosine)
 Dipyridamole
 /aspirin in polycythemia vera, Mar., 191
 /thallium myocardial perfusion imaging, June, 462-463
 Directives: advance, for Alzheimer's patients, Jan., 36-37
 Diuretics
 dosage variation, effects on blood pressure, blood chemistries, and lipids, Nov., 815
 in hypertension
 in diabetics, Nov., 823
 in elderly, Nov., 812-813, 822
 as initial therapy, Nov., 814-815
 Dizziness: in polycythemia vera, Mar., 171

DNA probes: in unknown primary malignancy, Apr., 243

Doppler echocardiography (see Echocardiography, Doppler)

Down's syndrome: Alzheimer's disease in, Jan., 26-27

Doxorubicin cardiotoxicity: endomyocardial biopsy in, June, 488

Doxycycline: in malignant pleural effusions, May, 294

Driving: and Alzheimer's disease, Jan., 37

Drugs

- in Alzheimer's disease, Jan., 49
- antihypertensive (*see* Drug, therapy in hypertension *below*)
- antiinflammatory (*see* Antiinflammatory agents)
- effect on urinary continence, Feb., 96
- induced lupus pleuritis, May, 318
- interfering, causing resistant hypertension, Nov., 821
- platelet dysfunction due to, Aug., 609-614
- reactions causing pleural effusions, May, 319
- therapy in hypertension, Nov., 809-826
 - clinical trial results, Nov., 810-812
 - costs, Nov., 825-826
 - in diabetics, Nov., 822-824
 - in elderly, Nov., 821-822, 823
 - in elderly, results, Nov., 812-814
 - exercise and, Nov., 805
 - individualizing, Nov., 815-816, 817
 - initial therapy, choice of, Nov., 814-815
 - renovascular, Nov., 819-821
 - resistant, Nov., 818-821
 - second choices, Nov., 816-818
 - sleep apnea and, Nov., 824-825
 - special problems, Nov., 821-825
 - subsequent choices, Nov., 816-818

- therapy in urinary incontinence, geriatric, Feb., 127-131
- mixed, Feb., 130-131
- overflow, Feb., 131
- stress, Feb., 130
- urge, Feb., 127-130
- toxicity causing dementia, Jan., 27-28
- use, IV, and HIV transmission, Sept., 661-662

Dyslipidemias: and hypertension, Nov., 788-790

Dyspnea

- abnormal, as end point of exercise testing, June, 413
- in cardiac evaluation, June, 357-358
- in polycythemia vera, Mar., 171

Dysproteinemias: platelet dysfunction in, Aug., 617

E

Ebstein's anomaly: echocardiography in, June, 439

ECG (*see* Electrocardiogram)

Echinococcosis: pleural, May, 310

Echocardiography, June, 417-455

- of aortic valve, bicuspid, June, 454
- of atrial enlargement, June, 450
- of cardiac masses, June, 451-453
- of cardiac tumors, June, 451-452
- of chamber enlargement and hypertrophy, June, 447-450
- of diastolic function, June, 446-447

Doppler, June, 428-430

- color-flow, June, 429-430
- continuous-wave, June, 429
- principles of Doppler signal measurement, June, 428-429
- pulsed-wave, June, 429

in endocarditis, infective, June, 440-441

for functional assessment, June, 441-451

in heart disease

- congenital, June, 453-454
- valvular, June, 430-431

limitations, technical, June, 430

in mitral valve prolapse, June, 436
 M-mode, June, 419-422
 at level of aortic valve, June, 423
 at level of mitral valve, June, 422
 at level of papillary muscles, June, 421
 of myxoma, June, 451
 in pericardial disease, June, 454-455
 in pericardial effusion, June, 454, 455
 in pericarditis, constrictive, June, 454-455
 in regurgitant lesions, June, 434-440
 in regurgitation
 aortic, June, 437, 438
 mitral, June, 435-437
 tricuspid, June, 437-440
 of septal defect, atrial and ventricular, June, 453-454
 in specific disease states, June, 430-455
 in stenosis
 aortic, June, 433-434
 mitral, June, 431-433
 in stenotic lesions, June, 431-434
 stress, June, 450-451
 of systolic function, June, 441-446
 left ventricular, June, 442-444
 left ventricular, in cardiomyopathy, dilated, June, 443-444
 left ventricular, in ischemic heart disease, June, 442-443
 right ventricular, June, 445-446
 in tamponade, cardiac, June, 454
 of thrombi, atrial and ventricular, June, 452-453
 transesophageal, June, 425-428
 two-dimensional, June, 422-425
 apical four-chamber view, June, 424-425, 427
 parasternal long-axis view, June, 423, 424, 425
 parasternal short-axis view, June, 423-424, 426
 subcostal views, June, 425

suprasternal view, June, 425
 of ventricular dilatation
 left, June, 447
 right, June, 447-448
 of ventricular hypertrophy
 left, June, 448-450
 right, June, 450

Edema

peripheral, in cardiac evaluation, June, 379-380
 pulmonary, on chest radiography, June, 404-405
 after resuscitation, Dec., 866-867
 Education: low, and risk of Alzheimer's disease, Jan., 14

Effusion

parapneumonic (see Parapneumonic effusions and bacterial infections of pleural space)
 pericardial (see Pericardial effusion)
 pleural (see Pleural effusion)
 Eicosapentanoate: effect on platelet function, Aug., 614

Elastic forces: of lung and chest wall at resting level in mechanical analogue, July, 527

Elastic properties, July, 521-531

Elderly

bacteriuria in, Feb., 90-91
 treatment, Feb., 91-92
 DDAVP in, Aug., 621
 hypertension in, drug therapy for, Nov., 821-822, 823
 results of trials, Nov., 812-814
 incontinence in, urinary (see Incontinence, urinary, geriatric)
 Electrical stimulators: in geriatric urinary incontinence, Feb., 133-134

Electrocardiogram, June, 380-397
 in atrial enlargement, June, 389-390
 left, June, 389-390
 right, June, 390
 in atrial tachycardia, multifocal, June, 392
 axis, June, 383-384
 in chamber enlargement, June, 387-392

Electrocardiogram (cont.)

- in cor pulmonale, June, 390-392
 - acute, June, 390
 - chronic, June, 391
- exercise, ST segment on abnormalities in, June, 413-414
- false positive responses, June, 414
- ischemic changes, June, 413-414
- lead(s)
 - limb, standard, June, 381-382
 - precordial, unipolar, June, 382-383
 - system, standard 12-lead, June, 381-384
- in myocardial infarction, June, 394-397
 - non-Q wave, June, 397
 - Q wave, June, 394-397
- in myocardial ischemia, June, 392-397
 - reversible, June, 393-394
 - normal, June, 380-387
 - normal sequence of activation, June, 384-387
- in pulmonary embolus, acute, June, 391
- vectors, June, 383-384
- in ventricular hypertrophy, left, June, 387-388
 - Romhilt-Estes point system, June, 389
 - Sokolow-Lyons criteria, June, 389
- in ventricular hypertrophy, right, June, 388-389
- Electromyography: in geriatric urinary incontinence, Feb., 116
- Electron
 - microscopy in malignancy of unknown primary origin, Apr., 240-241
 - transport in multiple organ failure syndrome, Dec., 876
- EMG: in geriatric urinary incontinence, Feb., 116
- Emphysema: compliance in, July, 523

- Empyema: differentiated from lung abscess, May, 301
- Enalapril: in diabetic nephropathy, Nov., 824
- Encephalitis: toxoplasmic, in AIDS, Oct., 727
- Encephalopathy: spongiform, Jan., 34
- Endocarditis, infective, echocardiography in, June, 440-441
 - transesophageal, June, 428
- Endocrine disorders: and polycythemia, Mar., 186
- Endocrinopathies: and dementia, Jan., 31-32
- Endomyocardial biopsy, June, 487-490
- Endoscopic variceal sclerotherapy: pleural effusions after, May, 316
- Endothelial cells: in multiple organ failure syndrome, Dec., 875-876
- Endotoxin: antibodies against, in treatment of multiple organ failure syndrome, Dec., 884
- Enema: barium, in unknown primary malignancy, Apr., 229
- Energy
 - consumption during exercise, July, 567
 - expenditure in multiple organ failure syndrome, Dec., 867-869
 - supply/demand ratio impairment during exercise, July, 571
- Environmental manipulation: in geriatric urinary incontinence, Feb., 119-120
- Enzyme
 - immunoassay in HIV diagnosis, Sept., 672-673
 - inhibitors, angiotensin-converting, in hypertension in diabetics, Nov., 823-824
- Eosinophil protein-induced storage pool deficiency: platelet dysfunction in, Aug., 619
- Epidermal growth factor: in breast cancer, Apr., 246

- Epigastric distress: in polycythemia vera, Mar., 171
- Epinephrine-induced platelet aggregation, Aug., 593-594
- Epsilon amino caproic acid: for platelet function disorders, Aug., 622
- Epstein-Barr virus infection: in AIDS, Oct., 735
- Epstein's syndrome, Aug., 602
- Ergotamine: causing pleural effusion, May, 319
- Erythroid colonies: in polycythemia vera, Mar., 168
- Erythrokinetic studies: in postpolycythemic myeloid metaplasia, Mar., 200
- Erythromelalgia: in polycythemia vera, Mar., 172
- Erythropoiesis
control of, Mar., 167
normal and pathological, Mar., 167
- Erythropoietin
levels after zidovudine in AIDS, Oct., 710
production increase causing secondary polycythemia
appropriate, Mar., 185-186
inappropriate, Mar., 186
recombinant, in postpolycythemic myeloid metaplasia, Mar., 202
- Esophagitis: *Candida*, in AIDS, Oct., 740-741
- Esophagus
perforation, pleural effusions after, May, 314-315
ulcerations, zidovudine-induced, Oct., 710
- Estrogen
/alpha agonist in geriatric stress urinary incontinence, Feb., 130
conjugated
in platelet function disorders, Aug., 621
in uremic patients, Aug., 615
decrease, effect on micturition, Feb., 87
/imipramine in geriatric mixed urinary incontinence, Feb., 130-131
replacement therapy, risks, Feb., 119
- Ethchlorvynol: causing pleural effusion, May, 319
- Examination
abdominal, in cardiac evaluation, June, 379
cardiac, June, 368-378
chest, in cardiac evaluation, June, 378-379
extremity, in cardiac evaluation, June, 379-380
neurologic, in Alzheimer's disease, Jan., 22-23
physical (see Physical, examination)
- Exercise
cardiorespiratory adaptation to, July, 566-571
poor cooperation and, July, 571
cardiovascular limitation during, July, 569-570
ECG (see Electrocardiogram, exercise)
energy consumption during, July, 567
energy supply/demand ratio impairment during, July, 571
first-pass nuclear cardiology studies during, June, 458
gas exchange during, abnormal, July, 568-569
handgrip, cardiac auscultation during, June, 378
oxygen consumption during, July, 567
pelvic muscle, for geriatric incontinence, Feb., 121
physiology, cardiac, June, 411-415
prediction equations for, July, 576
pulmonary vascular disease and, July, 570-571
respiratory quotient during, July, 570
testing, June, 410-417
arrhythmias induced by, June, 415

blood pressure response during, abnormal, June, 414
 Bruce protocol, June, 415-416
 complications, June, 416-417
 end point(s), angina as, June, 413
 end point(s), dyspnea as, abnormal, June, 413
 end point(s), fatigue as, June, 413
 end point(s), ischemic, June, 412-413
 end point(s), normal, June, 412-413
 physical findings during, abnormal, June, 415
 treadmill, after myocardial infarction, June, 416
 types, June, 415-416
 thallium imaging, June, 461-462
 ventilatory limitation during, July, 566-568

Expiration: forced, snapshot of forces acting in chest during, July, 544

Expiratory
 flow-volume relationships, July, 551
 reserve volume, July, 527

Extragenital germ cell tumor, Apr., 251
 immunocytochemical stain in, Apr., 236

Extrapyramidal signs: in Alzheimer's disease, Jan., 20, 22

Extremity examination: in cardiac evaluation, June, 379-380

F

Fat: dietary, and hypertension, Nov., 808

Fatigue
 as end point of exercise testing, June, 413
 respiratory muscle, July, 553

Fatty acids
 omega-3, in multiple organ failure syndrome, Dec., 886
 turnover after resuscitation, Dec., 870

α -Fetoprotein
 immunocytochemical stain for, in extragenital germ cell tumor, Apr., 236
 in malignancy of unknown primary origin, Apr., 231-232

Fever
 after catheterization, chronic indwelling urinary, in elderly, Feb., 136
 Mediterranean, familial, causing pleural disease, May, 318-319
 Q, causing pleural effusions, May, 312

Fibrinogen: and platelet aggregation, Aug., 596-597

Fibronectin receptor: on platelets, Aug., 591, 596-597

Fibrosis: pulmonary, compliance in, July, 523

Fish
 consumption, effect on platelet function, Aug., 614
 oils and hypertension, Nov., 808

566C80 in AIDS
 for *Pneumocystis carinii* disease, Oct., 723, 724
 for toxoplasmosis, Oct., 728

Flow cytometry: in exudative pleural effusions, May, 282

Flow resistance, July, 532-538
 (See also Airway, resistance)
 in asthma, July, 534
 estimated from forced vital capacity, July, 537
 in peripheral airways, July, 543
 measurement in body plethysmograph, July, 535

Flow-volume relationships
 expiratory, examples of, July, 551
 during forced vital capacity maneuver, July, 537
 inspiratory, July, 551-552
 examples of, July, 551

FLT: in AIDS, Oct., 715

Fluconazole in AIDS
 for candidiasis, Oct., 741
 for cryptococcosis, Oct., 742-743

Flucytosine: in cryptococcosis in AIDS, Oct., 742-743

Fluid

- management in multiple organ failure syndrome, Dec., 882
- pleural (*see* Pleural, fluid)
- 5-Fluorocytosine: in pleural cryptococcosis, May, 308
- Fluorodeoxythymidine: in AIDS, Oct., 715
- Fluoxetine: weight gain and smoking cessation, Nov., 800
- Fontan procedure: pleural effusion after, May, 291
- Forced expiration: snapshot of forces acting in chest during, July, 544
- Forced vital capacity, July, 536–538
 - flow resistance estimated from, July, 537
 - maneuver, flow-volume relationship during, July, 537
- Forgetfulness: benign senescent, Jan., 17
- Foscarnet in AIDS
 - for cytomegalovirus infection, Oct., 732–733
 - for herpes simplex virus infection, Oct., 734
 - for varicella-zoster virus infection, Oct., 735
- Fracture: hip, and imipramine in geriatric urinary incontinence, Feb., 127
- Friction rub: pericardial, June, 374, 377
- Frontal lobe dementia, Jan., 33
- Functional residual capacity, July, 527
- Fungus
 - Chinese black tree, causing platelet dysfunction, Aug., 613
 - infections
 - in AIDS, Oct., 740–744
 - of pleural space, May, 307–309

G

- Gallium-67 scans: in unknown primary malignancy, Apr., 229
- Gallop: summation, June, 372

Ganciclovir in AIDS

- for cytomegalovirus infection, Oct., 732
- for leukoplakia, oral hairy, Oct., 735
- Garlic extracts: causing platelet dysfunction, Aug., 613
- Garments: absorbent, for geriatric urinary incontinence, Feb., 120
- Gas
 - diffusion, July, 559
 - distribution, July, 544–546
 - exchange, July, 553–559
 - abnormal, during exercise, July, 568–569
 - disturbances, July, 555
 - prediction equations for, July, 576
 - transport in blood, July, 559–564
- Gastric
 - biopsy, aspirin, and platelet dysfunction, Aug., 611
 - cancer, CA 19-9 in, Apr., 234
- Gastrointestinal
 - radiography in unknown primary malignancy, Apr., 229
 - tract disease
 - cytomegalovirus, in AIDS, Oct., 731
 - pleural effusions due to, May, 313–316
- Gaucher's disease: platelet dysfunction in, Aug., 618
- Genes
 - for glycoprotein IIb and IIIa, Aug., 604
 - heat shock, in multiple organ failure syndrome, Dec., 878
- Genetics
 - (*See also* Cytogenetics)
 - of Alzheimer's disease, Jan., 26–27
- Geriatric (*see* Elderly)
- Germ cell tumor
 - extragonadal, Apr., 251
 - immunocytochemical stain in, Apr., 236
 - gonadal, Apr., 251
- Gerstmann-Straussler-Scheinker disease, Jan., 34

- Giardia lamblia* infection: in AIDS, Oct., 730
- Glanzmann thrombasthenia, Aug., 603-605
- Glaucoma: and oxybutynin in geriatric urinary incontinence, Feb., 127
- Glomerular filtration rate: effect of enalapril or metoprolol in diabetic nephropathy on, Nov., 824
- Glucose
intolerance and upper body obesity, Nov., 790
metabolism in multiple organ failure syndrome, Dec., 869-870
pleural fluid, in pleural effusions exudative, May, 282
malignant, May, 293
- Glycolysis: aerobic, in multiple organ failure syndrome, Dec., 867-869
- Glycoprotein
Ia/IIa deficiency, Aug., 602-603
Ib, Aug., 591
Ib/IX
complex, Aug., 591
deficiency, Aug., 600-602
Ic/IIa deficiency, Aug., 602-603
IIb, gene for, Aug., 604
IIb/IIIa, Aug., 591
complex and platelet aggregation, Aug., 596-597
deficiency, Aug., 603-605
IIIa, gene for, Aug., 604
- Gonadal germ cell tumors: of unknown primary origin, Apr., 251
- Gonadotropin: human chorionic, in unknown primary malignancy, Apr., 232
- Gout: in polycythemia vera, Mar., 182
- gp160: recombinant, in AIDS, Oct., 720
- Granulocytes: in polycythemia vera, Mar., 177-178
- Granulovacuolar degeneration: in Alzheimer's disease, Jan., 44
- Gray platelet syndrome, Aug., 602, 606-607
- Greco syndrome, Apr., 251-252
- Growth factor
epidermal, in breast cancer, Apr., 246
insulin-like, causing hypoglycemia in benign mesothelioma, May, 298
nerve, in Alzheimer's disease, Jan., 48-49
platelet-derived, Aug., 597
- Guardianship: and Alzheimer's disease, Jan., 37
- Gut
barrier functions, failure in multiple organ failure syndrome, Dec., 879
decontamination, selective, in multiple organ failure syndrome, Dec., 879-880
- ## H
- habit training: for geriatric urinary incontinence, Feb., 124-125
- Haemophilus influenzae* infections: in AIDS, Oct., 744
- Hairy
cell leukemia, platelet dysfunction in, Aug., 618
leukoplakia, oral, in AIDS, Oct., 735
- Haloperidol: in Alzheimer's disease, Jan., 38-39
- Handgrip: cardiac auscultation during, June, 378
- Harrington rod spinal fusion: DDAVP in, Aug., 621
- HCG: in unknown primary malignancy, Apr., 232
- Head trauma: as risk factor in Alzheimer's disease, Jan., 15
- Headache: in polycythemia vera, Mar., 170-171
- Health
care workers, HIV transmission to, Sept., 665-667
psychological, effect of geriatric urinary incontinence on, Feb., 82-83

- public health impact of Alzheimer's disease, Jan., 13-16
- Heart
 - appearance on chest radiography, normal (*see* Radiography, chest, cardiac appearance on, normal)
 - auscultation (*see* Auscultation, cardiac)
 - bypass (*see* Bypass, cardiac)
 - catheterization (*see* Catheterization, cardiac)
 - chamber
 - enlargement, ECG in, June, 387-392
 - enlargement, echocardiography, June, 447-450
 - enlargement, on radiography, chest, June, 399-402
 - hypertrophy, echocardiography, June, 447-450
 - disease
 - congenital, echocardiography in, June, 453-454
 - congenital, MRI in, June, 465
 - congenital, on radiography, chest, June, 405-409
 - coronary, deaths from, relation to cholesterol, blood pressure, and smoking, Nov., 789
 - coronary, fatal, effect of drug therapy in hypertension on, Nov., 811
 - ischemic, echocardiography of left ventricular systolic function in, June, 442-443
 - ischemic, MRI in, June, 464
 - valvular, cardiac catheterization in, June, 470-483
 - valvular, echocardiography in, June, 430-431
 - dysfunction in multiple organ failure syndrome, Dec., 863-864
 - evaluation, June, 355-503
 - abdominal examination in, June, 379
 - arterial pressures in, June, 365-368
 - arterial pulse in, June, 366-368
 - arterial pulse wave configuration in, abnormal, June, 367-368
 - arterial pulse wave configuration in, normal, June, 366-367
 - blood pressure measurement in, June, 365-366
 - cardiac catheterization in (*see* Catheterization, cardiac)
 - chest examination in, June, 378-379
 - chest pain in, June, 357-358
 - clubbing in, June, 380
 - cough in, June, 362
 - dyspnea in, June, 357-358
 - edema in, peripheral, June, 379-380
 - electrocardiogram in (*see* Electrocardiogram)
 - exercise testing in (*see* Exercise, testing)
 - extremity examination in, June, 379-380
 - hemoptysis in, June, 360-362
 - imaging in, magnetic resonance (*see* Magnetic resonance imaging, in cardiac evaluation)
 - imaging in, myocardial perfusion (*see* Myocardial, perfusion imaging)
 - physical examination in, June, 362-380
 - radiography in, chest, June, 397-410
 - symptoms in, June, 356-357
 - syncope in, June, 359-360
 - tissue perfusion in, June, 380
 - venous pressure(s) in, June, 362-365
 - venous pressure wave configuration in, abnormalities, June, 364-365
 - venous pressure wave configuration in, normal, June, 362-364
 - examination, June, 368-378
 - exercise physiology, June, 411-415
 - failure, congestive

Heart (*cont.*)

- early, on chest radiography, June, 403-404
- pleural effusion due to (*see* Pleural effusion, heart failure causing, congestive)
- radiography in, chest, June, 402-405
- function assessment
 - by echocardiography, June, 441-451
 - by nuclear cardiology techniques, June, 456-459
- masses, echocardiography, June, 451-453
- murmurs (*see* Murmurs, cardiac)
- palpation, June, 368-369
- postcardiac injury syndrome causing pleural effusions, May, 320-321
- sounds (*see* Sounds, heart)
- tamponade (*see* Tamponade, cardiac)
- tumors
 - echocardiography in, June, 451-452
 - echocardiography in, transthoracic, June, 428
 - MRI of, June, 465
- Heat shock genes: in multiple organ failure syndrome, Dec., 878
- Helical filaments: in Alzheimer's disease, Jan., 43-44
- Hemangioma: cerebellar, and polycythemia, Mar., 186
- Hematocrit
 - correlation between red cell mass and, Mar., 174
 - increased
 - and increased red cell mass in differential diagnosis of polycythemia vera, Mar., 184-188
 - and normal red cell mass in differential diagnosis of polycythemia vera, Mar., 183-184
- Hematologic toxicity: of zidovudine, Oct., 709-710
- Hematopoiesis: scheme of, Mar., 166
- Hemochromatosis: endomyocardial biopsy in, June, 488
- Hemodialysis: in multiple organ failure syndrome, Dec., 860
- Hemodynamic assessment
 - of aortic regurgitation, June, 482
 - of mitral regurgitation, June, 479
- Hemoglobin: congenital abnormal, causing polycythemia, Mar., 185
- Hemoptysis: in cardiac evaluation, June, 360-362
- Hemorrhage: pathological, in polycythemia vera, Mar., 172
- Heparin: causing platelet dysfunction, Aug., 613
- Hepatic
 - (*See also* Liver)
 - hydrothorax (*see* Hydrothorax, hepatic)
 - vein thrombosis and polycythemia vera, Mar., 171
- Hepatitis B transmission: to health care workers, Sept., 666
- Hepatobiliary cancer: CA 19-9 in, Apr., 234
- Hepatomas: and polycythemia, Mar., 186
- Hermansky-Pudlack syndrome, Aug., 608
- Hernia: diaphragmatic, and pleural effusion, May, 316
- Herpes
 - simplex virus infection in AIDS, Oct., 733-734
 - zoster and HIV infection, Sept., 671
- Heterosexual HIV transmission, Sept., 659-660
- Hexabrix: in diagnosis of pleural effusions after esophageal perforation, May, 315
- Hip
 - fracture, and imipramine in geriatric urinary incontinence, Feb., 127
 - replacement, intermittent catheterization after, in elderly, Feb., 135
- Hirano bodies: in Alzheimer's disease, Jan., 44

- Histamine
 inhaled, effect on airway resistance, July, 550
 in polycythemia vera, Mar., 177
- Histoplasma capsulatum* infection:
 in AIDS, Oct., 743
- Histoplasmosis: pleural, May, 308-309
- History: in geriatric urinary incontinence evaluation, Feb., 101-102
- HIV, Sept., 647-652
 (See also AIDS)
 antigen in HIV diagnosis, Sept., 675-676
 diagnosis
 enzyme immunoassay in, Sept., 672-673
 HIV antigen in, Sept., 675-676
 viral culture in, Sept., 677-678
 Western blot in, Sept., 673-675
 infection
 clinical stages, Sept., 656
 infections, malignancies, and neurologic syndromes associated with, Sept., 657
 polymerase chain reaction for, Sept., 678-679
- 1
 replication, Sept., 651
 structural characteristics, basic, Sept., 649
- testing, Sept., 669, 672-679
- transmission, Sept., 658-667
 by blood products, Sept., 663-664
 to health care workers, Sept., 665-667
 by intravenous drug use, Sept., 661-662
 perinatal, Sept., 662-663
 sexual, Sept., 659-661
 by transplantation, Sept., 664
- Hodgkin's disease: in AIDS, Oct., 750
- Home (see Nursing home)
- Homosexual men: HIV transmission by, Sept., 659
- Hormone receptors: in unknown primary malignancy, Apr., 241
- Hospice care: in Alzheimer's disease, Jan., 36
- HTLV-III infection: in AIDS, Oct., 736
- Human immunodeficiency virus (see HIV)
- Human T cell lymphotropic virus-III infection: in AIDS, Oct., 736
- Huntington's disease: dementia in, Jan., 33-34
- Hyaluronic levels: in pleural fluid, in malignant mesothelioma, May, 297
- Hydatid disease: pleural, May, 310
- Hyderygine: in Alzheimer's disease, Jan., 49
- Hydrocephalic dementia: symptomatic, Jan., 30
- Hydrochlorothiazide: in hypertension, in elderly, Nov., 822
- Hydroergotoxine: in Alzheimer's disease, Jan., 49
- Hydrolases: acid, in platelet lysosomes, Aug., 598
- Hydronephrosis: and polycythemia, Mar., 186
- Hydrothorax, hepatic, May, 288-289
 clinical manifestations, May, 289
 diagnosis, May, 289
 pathophysiology, May, 288-289
 treatment, May, 289
- Hydroxynaphthoquinone 566C80 (see 566C80)
- Hydroxyurea
 in myeloid metaplasia, postpolycythemic, Mar., 202
 in myeloproliferative disorders, Aug., 618
 in polycythemia vera, Mar., 193-195
 red cell volume increase after, Mar., 176
- Hypercholesterolemia: and hypertension, Nov., 788-789
- Hypernephroma: and polycythemia, Mar., 186
- Hyperreflexia: detrusor, causing urge incontinence, in elderly, Feb., 98

- Hypertension, Nov., 783-838
 alcohol moderation in, Nov., 803
 caffeine and, Nov., 808-809
 calcium supplements in, Nov., 806
 coffee and, Nov., 808-809
 drug therapy in (*see* Drug, therapy in hypertension)
 dyslipidemias and, Nov., 788-790
 fat and, Nov., 808
 fish oils and, Nov., 808
 insulin resistance and, Nov., 790-792
 magnesium supplements in, Nov., 806
 management, Nov., 783-838
 (*See also* therapy below)
 conclusion, Nov., 829-830
 obesity and, upper body, Nov., 790
 physical activity in, Nov., 804-805
 in polycythemia vera, Mar., 173
 potassium intake increase in, Nov., 805-806
 pulmonary, chest pain in, June, 359
 refractory, causes, Nov., 818
 renin activity and, plasma, Nov., 793-794
 renovascular
 clinical clues for, Nov., 820
 drug therapy in, Nov., 819-821
 screening tests for, Nov., 820
 resistant
 drug therapy in, Nov., 818-821
 interfering drugs causing, Nov., 821
 risk factors, alterable, assessment of, Nov., 788-795
 overall, Nov., 794
 smoking cessation and, Nov., 795, 798-799
 sodium restriction in, Nov., 800-803
 stress management in, Nov., 806-808
 therapy
 (*See also* management above)
 blood pressure monitoring during, Nov., 786-787
 goal of, Nov., 826-829
 J-curve phenomenon and, Nov., 828, 829
 life-style modifications for (*see* Life-style modifications for treatment of hypertension)
 ventricular hypertrophy and, left, Nov., 792-793
 weight reduction in, Nov., 799-800
- Hyperthyroidism: and dementia, Jan., 31
- Hypertriglyceridemia
 in HIV infection, Sept., 672
 obesity and upper body, Nov., 790
- Hypertrophic cardiomyopathy: endomyocardial biopsy in, June, 487-488
- Hypertrophy
 chamber, echocardiography, June, 447-450
 ventricular, left
 ECG in (*see* Electrocardiogram, in ventricular hypertrophy, left)
 echocardiography, June, 448-450
 hypertension and, Nov., 792-793
 ventricular, right
 ECG in, June, 388-389
 echocardiography, June, 450
- Hypocholesterolemia: in HIV infection, Sept., 672
- Hypoglycemia: in benign mesothelioma due to insulin-like growth factor, May, 298
- Hypothyroidism: and dementia, Jan., 31
- Hypoventilation: alveolar, and polycythemia, Mar., 185
- Hypoxemia
 arterial, causing polycythemia, Mar., 185
 respiratory response to, July, 565

I

Imaging

- magnetic resonance (*see* Magnetic resonance imaging)
 in malignancy of unknown primary origin, Apr., 229

- myocardial perfusion (see Myocardial, perfusion imaging)
- nuclear, principles, June, 456
- radionuclide, in unknown primary malignancy, Apr., 229-230
- sound wave, principles, June, 417-419
- Imipramine
 - in depression in Alzheimer's disease, Jan., 38
 - in incontinence, geriatric urinary mixed, Feb., 130-131
 - urge, Feb., 127
- Immune disorder: and acquired thrombasthenia, Aug., 605
- Immunoassay: enzyme, in HIV diagnosis, Sept., 672-673
- Immunoblastic lymphadenopathy: causing pleural disease, May, 319
- Immunocytochemistry
 - in germ cell tumor, extragonadal, Apr., 236
 - in malignancy of unknown primary origin, Apr., 235-240
 - screening panel of, Apr., 238-239
- Immunodeficiency
 - syndrome, acquired (see AIDS)
 - virus, human (see HIV)
- Immunofluorescence: indirect, in HIV diagnosis, Sept., 675
- Immunologic studies: in exudative pleural effusions, May, 284
- Immunomodulators: in AIDS, Oct., 720
- Impulse, ventricular
 - left, apical, June, 368
 - right, June, 369
- Incontinence, urinary, geriatric, Feb., 77-149
 - absorbent pads and garments for, Feb., 120
 - acute form, Feb., 94-96
 - adverse effects, Feb., 82-83
 - artificial sphincter in, Feb., 133
 - behavioral therapies in (see Behavioral, therapies in geriatric urinary incontinence)
 - catheter(s) in, Feb., 134-138
 - external, Feb., 134
 - indwelling, chronic, Feb., 135-138
 - catheterization in, intermittent, Feb., 135
 - clamps for, Feb., 132-133
 - classification, clinical, Feb., 94-100
 - costs, Feb., 83
 - definition, Feb., 78-79
 - devices for, Feb., 132-134
 - diagnostic evaluation, Feb., 100-117
 - bladder records in (see Bladder, records)
 - clinical assessment in, initial, Feb., 101-112
 - components of, Feb., 101
 - criteria for referral, Feb., 112, 114-115
 - cystometrogram in (see Cystometrogram)
 - cystometry in, simple, Feb., 111
 - cystourethroscopy in, Feb., 113
 - electromyography in, Feb., 116
 - further, Feb., 113-117
 - history in, Feb., 101-102
 - laboratory studies in, Feb., 106
 - overview, Feb., 100-101
 - physical examination in, Feb., 103, 106
 - radiography in, Feb., 113
 - urethral pressure profile in, Feb., 116-117
 - urodynamic testing in (see Urodynamic testing in geriatric urinary incontinence)
 - uroflowmetry in, Feb., 116
 - drug therapy in, Feb., 127-131
 - electrical stimulators in, Feb., 133-134
 - environmental manipulation in, Feb., 119-120
 - functional, Feb., 99-100
 - definition and causes, Feb., 97
 - general issues, Feb., 78-83
 - incidence, Feb., 80-81
 - mixed, Feb., 100
 - drug therapy in, Feb., 130-131

Incontinence (*cont.*)

- overflow, Feb., 99
 - definition and causes, Feb., 97
 - drug therapy in, Feb., 131
 - pathophysiologic considerations, Feb., 83-94
 - pathophysiology, basic, Feb., 93-94
 - persistent forms, Feb., 96-100
 - definitions and causes, Feb., 97
 - pessaries in, Feb., 133
 - physiologic considerations, Feb., 83-94
 - prevalence, Feb., 80-81
 - prompted voiding protocol for, example, Feb., 126
 - requirements for, Feb., 92-93
 - reversible factors contributing to, Feb., 95
 - treatment, Feb., 117-119
 - reversible form, Feb., 94-96
 - stress, Feb., 97-98
 - definition and causes, Feb., 97
 - drug therapy in, Feb., 130
 - surgery in, Feb., 131-132
 - treatment, Feb., 117-132
 - nonspecific measures, Feb., 119-120
 - overview, Feb., 117
 - unconscious, Feb., 98
 - urge, Feb., 98-99
 - definition and causes, Feb., 97
 - drug therapy in, Feb., 127-130
 - urinary tract abnormalities underlying lower, Feb., 93
- Infarction
- myocardial (*see* Myocardial, infarction)
 - pulmonary, causing hemoptysis in mitral stenosis, June, 361-362
- Infections
- associated with AIDS and advanced HIV infection, Sept., 657
 - nosocomial, in multiple organ failure syndrome, Dec., 878-880
- Infectious complications: of AIDS, Oct., 720-745

- Infective endocarditis, echocardiography in, June, 440-441
- transesophageal, June, 428
- Inflammatory
- disease, pelvic, and AIDS, Oct., 744-745
 - myocarditis, endomyocardial biopsy in, June, 487
 - response syndrome, systemic (*see* Systemic inflammatory response syndrome)
- Innervation: basic, of lower urinary tract, Feb., 85
- Insect transmission: of HIV, Sept., 665
- Insemination: artificial, HIV transmission by, Sept., 664
- Inspiratory
- capacity, July, 527
 - flow-volume relationship, July, 551-552
 - examples of, July, 551
 - reserve volume, July, 527
- Insulin
- like growth factor causing hypoglycemia in benign mesothelioma, May, 298
 - resistance
 - factors in, Nov., 791
 - hypertension and, Nov., 790-792
- Intensive care unit: multiple organ failure syndrome after, Dec., 886-887
- Interferon
- alpha
 - in Kaposi's sarcoma in AIDS, Oct., 747
 - /zidovudine in AIDS, Oct., 716
 - gamma levels in tuberculous pleural effusions, May, 285
 - in myeloid metaplasia, postpolycythemic, Mar., 202
 - in polycythemia vera, Mar., 196
- Interleukin-2: in metastatic melanoma, Apr., 245
- Intra-abdominal abscess: and pleural effusion, May, 315-316
- Intravenous drug use: and HIV transmission, Sept., 661-662

Irradiation

in Kaposi's sarcoma in AIDS, Oct., 747-748

spleen, in postpolycythemic myeloid metaplasia, Mar., 204

Ischemia, myocardial, ECG in, June, 392-397

reversible, June, 393-394

Ischemic

end point of exercise testing, June, 412-413

heart disease (see Heart, disease, ischemic)

ST segment changes during exercise testing, June, 413-414

Isoniazid

in pleural effusions, tuberculous, May, 306

in tuberculosis, in AIDS, Oct., 739

Isonitrite myocardial perfusion imaging, June, 463

Isosporiasis: in AIDS, Oct., 729-730

Itraconazole in AIDS

for aspergillosis, Oct., 744

for candidiasis, Oct., 741

for coccidioidomycosis, Oct., 744

for histoplasmosis, Oct., 743

J

J-curve phenomenon: and hypertension therapy, Nov., 828, 829

Joint symptoms: in polycythemia vera, Mar., 171

Jugular venous pressure tracing: in cardiac evaluation, June, 364

K

Kaposi's sarcoma in AIDS, Oct., 746-748

pleural effusions and, May, 311

Kegel exercises: for geriatric incontinence, Feb., 121

Ketoconazole

in blastomycosis, pleural, May, 307

in candidiasis in AIDS, Oct., 741

in histoplasmosis in AIDS, Oct., 743

Ketones: plasma, after resuscitation, Dec., 870

Kidney

cysts and polycythemia, Mar., 186

disease, polycystic, and polycythemia, Mar., 186

tumors and polycythemia, Mar., 186

Killer cells: lymphokine-activated, in metastatic melanoma, Apr., 245

Klinefelter's syndrome: and mediastinal germ cell tumors, Apr., 251

Korsakoff's syndrome, Jan., 30-31

Kuru, Jan., 34

Kussmaul's sign, June, 365

L

Laboratory

findings in polycythemia vera

(see Polycythemia, vera, laboratory findings in)

studies in geriatric urinary incontinence, Feb., 106

tests in pleural effusions, costs of, May, 279-280

Lactate production: after resuscitation, Dec., 867-869

Lactic dehydrogenase

pleural fluid, in exudative pleural effusions, May, 283

in polycythemia vera, Mar., 182

Laminin receptor: on platelets, Aug., 591

Lavage: bronchoalveolar, in diagnosis of *Pneumocystis carinii* pneumonia in AIDS, Oct., 722

LDH (see Lactic dehydrogenase)

Leads, ECG (see Electrocardiogram, leads)

Legionella infections: in AIDS, Oct., 745

Leishmania donovani infection: in AIDS, Oct., 730

Lentivirinae, Sept., 647-648

Letrazuril: in cryptosporidiosis in AIDS, Oct., 729

- Leucovorin in AIDS
 - for *Pneumocystis carinii* disease, Oct., 723
 - for toxoplasmosis, Oct., 727-728
- Leukemia
 - acute, after splenectomy in post-polycythemic myeloid metaplasia, Mar., 201
 - hairy cell, platelet dysfunction in, Aug., 618
 - myeloid
 - platelet dysfunction in, Aug., 618
 - in polycythemia vera, Mar., 198
- Leukocyte
 - alkaline phosphatase in polycythemia vera, Mar., 177, 178
 - count
 - in pleural effusions, exudative, May, 281-282
 - in polycythemia vera, Mar., 177
 - differential in exudative pleural effusions, May, 281-282
- Leukoencephalopathy: multifocal, in AIDS, Oct., 736
- Leukopenia: zidovudine-induced, Oct., 710
- Leukoplakia: oral hairy, in AIDS, Oct., 735
- Life-style modifications for treatment of hypertension, Nov., 795-809
 - combination therapies, Nov., 796-797
 - conclusion, Nov., 809
 - individual, Nov., 797-798
- Light microscopy: in malignancy of unknown primary origin, Apr., 235
- Linkage analysis: in Huntington's disease, Jan., 34
- Lipids: effects of diuretic dosage on, Nov., 815
- Listeria* infections: in AIDS, Oct., 745
- Lithium: in Alzheimer's disease, Jan., 39
- Liver
 - (See also Hepatic)
 - disease, platelet dysfunction in, Aug., 616
 - palpable, in polycythemia vera, Mar., 173
 - scans in unknown primary malignancy, Apr., 229
- Loxepine: in Alzheimer's disease, Jan., 38
- L-697, 639 and L-697, 661: in AIDS, Oct., 715-716
- Lung
 - (See also Pulmonary)
 - abscess differentiated from empyema, May, 301
 - capacity
 - closing, July, 548
 - total, subdivisions of lung volume as proportion of, July, 526
 - compliance, July, 522
 - dynamic, effect of increase in respiratory frequency on, July, 548
 - in emphysema, July, 523
 - in fibrosis, July, 523
 - frequency dependence of, July, 546-548
 - disease
 - chronic, pulsus paradoxus in, June, 368
 - mixed, lung volume in, July, 530
 - mixed, volume-pressure relationship in, July, 531
 - obstructive (see below)
 - polycythemia and, Mar., 185
 - restrictive (see below)
 - disease, obstructive
 - lung volume in, July, 530
 - ventilatory function disturbances in, July, 538
 - ventilatory pattern in, July, 539, 540-541
 - ventilatory pattern in, post-bronchodilator studies, July, 540, 541, 542
 - disease, restrictive
 - exercise in, relationship between respiratory rate and tidal volume during, July, 568
 - lung volume in, July, 530
 - ventilatory function disturbances in, July, 538

ventilatory pattern in, July, 538-539
 volume-pressure curve in, static, July, 525
 trapped, causing pleural effusion, May, 323
 unit disturbances, peripheral, July, 541-548
 volume, July, 526-531
 calculation, physical method of, July, 529
 closing, July, 548
 -flow relationships (*see* Flow-volume relationships)
 in healthy vs. ill individuals, July, 530
 prediction equations for, July, 575
 -pressure curve, static, in air-flow limitation, July, 525
 -pressure curve, static, in healthy individual, July, 524
 -pressure curve, static, in restrictive disorder, July, 525
 -pressure relationship, effect of localized airway obstruction on, July, 547
 -pressure relationship in mixed disorder, July, 531
 relationship between airway conductance and, July, 536
 relationship between airway resistance and, July, 536
 subdivisions, July, 526
 Lupus pleuritis, May, 317-318
 Lymphadenopathy
 in HIV infection, Sept., 671
 immunoblastic, causing pleural disease, May, 319
 Lymphatic clearance: of pleural fluid, May, 275
 Lymphocytes
 B, in HIV infection, Sept., 672
 T (*see* T cells)
 Lymphokine-activated killer cells: in metastatic melanoma, Apr., 245
 Lymphoma
 large-cell, Apr., 250-251

non-Hodgkin's, in AIDS, Oct., 748-749
 Epstein-Barr virus-associated, Oct., 735
 after zidovudine, Oct., 710
 Lymphotropic virus infection: I/II, human T cell, in AIDS, Oct., 736
 Lysosomes: platelet, Aug., 598
 Lysozyme levels: in polycythemia vera, Mar., 177

M

Macrophages
 in AIDS, Sept., 654-655
 in multiple organ failure syndrome, Dec., 874-875
 Magnesium supplements: in hypertension, Nov., 806
 Magnetic resonance imaging
 in Alzheimer's disease, Jan., 25
 in aortic disease, June, 465
 of bone marrow in polycythemia vera, Mar., 180
 in cardiac evaluation, June, 463-465
 principles, June, 464
 in specific disease states, June, 464
 in heart disease
 congenital, June, 465
 ischemic, June, 464
 of heart tumors, June, 465
 in malignancy of unknown origin, Apr., 230
 in pericardial disease, June, 464-465
 in Pick's disease, Jan., 33
 in toxoplasmic encephalitis in AIDS, Oct., 727
 Malaria: and HIV, Sept., 665
 Malignancy
 (*See also* specific malignancy)
 associated with AIDS and advanced HIV infection, Sept., 657
 of undetermined primary origin (*see* Unknown primary malignancy)

- Malnutrition:** in multiple organ failure syndrome, treatment of, Dec., 882-883
- Mammography:** in unknown primary malignancy, Apr., 229
- Mantoux tuberculin skin testing:** in AIDS, Oct., 739
- Marrow** (*see* Bone, marrow)
- Maximum voluntary ventilation,** July, 538
- May-Hegglin anomaly,** Aug., 602
- Mediastinal germ cell tumors:** and Klinefelter's syndrome, Apr., 251
- Medications** (*see* Drugs)
- Mediterranean fever:** familial, causing pleural disease, May, 318-319
- Megakaryocytes:** in polycythemia vera, Mar., 181
- Meigs syndrome:** pleural effusion in, May, 323-324
- Melanoma:** metastatic, interleukin-2 and lymphokine-activated killer cells in, Apr., 245
- Melphalan:** in polycythemia vera, Mar., 195
- Memory impairment:** age-associated, Jan., 17
- Mental status:** in HIV dementia after zidovudine, Oct., 709
- Mesothelioma**
 ovarian, Apr., 253-254
 peritoneal, Apr., 252-253
 pleural, benign, May, 297-298
 clinical manifestations, May, 298
 diagnosis, May, 298
 treatment, May, 298
 pleural, malignant, May, 296-297
 clinical manifestations, May, 296-297
 diagnosis, May, 297
 treatment, May, 297
- Metabolic acid-base disturbances,** July, 563-564
- Metabolism:** postresuscitative, Dec., 865-872
- Metaplasia** (*see* Myeloid, metaplasia)
- Metastases**
 pathophysiology, Apr., 224-227
 prostate cancer, immunocytochemical stain for prostate-specific antigen in, Apr., 237
- Metastatic**
 cascade, tumor-host interactions during, Apr., 224
 involvement in unknown primary malignancy, Apr., 223
 melanoma, lymphokine-activated killer cells and interleukin-2 in, Apr., 245
- Metformin:** in hypertension in diabetics, Nov., 824
- Methacholine:** inhaled, effect on airway resistance, July, 550
- Methylphenidate:** in depression in Alzheimer's disease, Jan., 38
- Methysergide:** causing pleural effusion, May, 319
- Metoprolol:** in diabetic nephropathy, Nov., 824
- Metronidazole**
 in isosporiasis in AIDS, Oct., 730
 pleural effusion due to, May, 319
- MIBI myocardial perfusion imaging:** technetium-99m, June, 463
- Microcirculation:** peripheral, oxygen extraction failure in, in multiple organ failure syndrome, Dec., 865
- Microscopy** in malignancy of unknown primary origin
 electron, Apr., 240-241
 light, Apr., 235
- Microsporidia infections:** in AIDS, Oct., 730
- Micturition** (*see* Urination)
- Mini-Mental Status Examination:** in Alzheimer's disease, Jan., 22
- Minocycline** in pleural effusions
 in congestive heart failure, May, 288
 malignant, May, 294, 295
- Mithramycin:** causing platelet dysfunction, Aug., 613
- Mitochondrial damage:** after zidovudine, Oct., 710

- Mitomycin: causing pleural effusion, May, 319
- Mitoxantrone: in malignant pleural effusions, May, 295
- Mitral
- regurgitation, June, 476-481
 - catheterization in, June, 477-479
 - catheterization in, for prognosis assessment, June, 479-481
 - echocardiography in, June, 435-437
 - hemodynamic assessment, June, 479
 - pathophysiology, June, 476-477
 - stenosis (see Stenosis, mitral)
 - valve prolapse, echocardiography in, June, 436
- MODS (see Multiple organ dysfunction syndrome)
- Molecular diagnostic methods: in unknown primary malignancy, Apr., 243
- Monitoring (see Blood, pressure, monitoring)
- Monoclonal antibody therapy: in multiple organ failure syndrome, Dec., 884-885
- Monocytes: in AIDS, Sept., 654-655
- Montreal platelet syndrome, Aug., 602
- Mortality (see Death)
- Moxalactam: and platelet function, Aug., 612
- MRI (see Magnetic resonance imaging)
- Multiple organ dysfunction syndrome
- (See also Multiple organ failure syndrome)
 - discussion of term, Dec., 856
 - progressive, characteristics of, Dec., 862
- Multiple organ failure syndrome, Dec., 855-895
- arginine in, Dec., 885
 - clinical characterization, Dec., 856-861
 - cytokine effects, Dec., 866
 - demographic data, Dec., 860
 - development, prediction of, Dec., 861
 - discriminators of survival, Dec., 860, 861
 - fatty acids in, ω -3, Dec., 886
 - glycolysis in, aerobic, Dec., 868
 - historical perspective, Dec., 855-856
 - after intensive care unit, Dec., 886-887
 - nosocomial infections in, Dec., 878-880
 - pathogenesis, Dec., 872-878
 - pathways, Dec., 858
 - postresuscitative metabolism, Dec., 865-872
 - postresuscitative physiologic response, Dec., 861-865
 - presentation, most common, Dec., 859
 - ribonucleic acid in, Dec., 885
 - summary, Dec., 887-888
 - therapy
 - current approach to, Dec., 880-883
 - new approaches to, Dec., 883-886
- Muramidase: in polycythemia vera, Mar., 177
- Murmur(s), cardiac, June, 372-378
- characteristics, June, 372, 374, 375
 - diastolic, characteristics, June, 376
 - intensity, June, 373-374
 - location, June, 374
 - quality, June, 374
 - radiation, June, 374
 - response to maneuvers, June, 374, 377-378
 - shape, June, 373
 - systolic, characteristics, June, 375
 - timing, June, 372-373
- Muscle
- pelvic, exercises, for geriatric incontinence, Feb., 121
 - respiratory (see Respiratory, muscle)

- Mycobacterial infections: in AIDS, Oct., 736-740
- Mycobacterium*
- avium* complex disease in AIDS, Oct., 736-738
- kansasii* infection in AIDS, Oct., 739-740
- tuberculosis* infection in AIDS, Oct., 738-739
- Myelodysplasia: Bernard-Soulier-like platelets in, in children, Aug., 602
- Myeloid
- leukemia (*see* Leukemia, myeloid)
- metaplasia, agnogenic, and age, Mar., 170
- metaplasia, postpolycythemic anemia in (*see* Anemia, in myeloid metaplasia, postpolycythemic)
- biopsy in, bone marrow, Mar., 200
- clinical course, Mar., 198-199
- erythrokinetic studies in, Mar., 200
- etiology, Mar., 169-170
- pathogenesis, Mar., 169-170
- spleen enlargement in, therapy, Mar., 203-204
- therapy, Mar., 199-204
- thrombocytopenia in, therapy, Mar., 203
- Myeloma: multiple, and acquired thrombasthenia, Aug., 605
- Myeloproliferative disorders: platelet dysfunction in, Aug., 617-618
- Myelosuppressive therapy: in polycythemia vera, Mar., 193-196
- Myocardial
- disease, cardiac catheterization in, June, 483-487
- infarction
- ECG in (*see* Electrocardiogram, in myocardial infarction)
- MRI in, June, 464
- treadmill testing after, June, 416
- ischemia, ECG in, June, 392-397
- reversible, June, 393-394
- perfusion imaging, June, 459-463
- isonitrile, June, 463
- thallium (*see* Thallium imaging)
- Myocarditis: inflammatory, endomyocardial biopsy in, June, 487
- Myoclonus: in Alzheimer's disease, Jan., 23
- Myomas: uterine, and polycythemia, Mar., 186
- Myopathy: zidovudine-induced, Oct., 710
- Myxedema: and pleural effusion, May, 291
- Myxoma: echocardiography, June, 451
- N**
- Nail: yellow nail syndrome, pleural effusion in, May, 322
- Needle
- biopsy (*see* Biopsy, pleural, needle)
- sticks and HIV, Sept., 665-666
- Neoplastic complications: of AIDS, Oct., 720-721, 746-750
- Nephropathy: diabetic, enalapril or metoprolol in, Nov., 824
- Nephrotic syndrome: pleural effusions in, May, 290
- Nerve growth factor: in Alzheimer's disease, Jan., 48-49
- Nervous system: central, lymphoma, in AIDS, Oct., 748-749
- Neuritic plaques: in Alzheimer's disease, Jan., 41-43
- Neurochemical anatomy: in Alzheimer's disease, Jan., 45-47
- Neuroendocrine carcinoma: poorly differentiated, Apr., 251-252
- Neurofibrillary tangles: in Alzheimer's disease, Jan., 43-44
- Neurohumoral system: in multiple organ failure syndrome, Dec., 874
- Neuroleptics
- for aggressiveness in Alzheimer's disease, Jan., 38-39
- sedating, for sleep/wake disturbances in Alzheimer's disease, Jan., 38

Neurologic

- examination in Alzheimer's disease, Jan., 22-23
- syndromes associated with advanced HIV infection and AIDS, Sept., 657
- Neuropathy, peripheral
 - didanosine-induced, Oct., 713
 - dideoxycytidine-induced, Oct., 715
- Neuropsychological performance tests: in dementia, Jan., 17, 22
- Neurotransmitters, aminergic, in Alzheimer's disease, Jan., 46
- cognitive therapy directed toward, Jan., 49
- Newborn: polymerase chain reaction for HIV infection in, Sept., 679
- Nimodipine: in Alzheimer's disease, Jan., 49
- NINCDS-ADRDA criteria
 - for Alzheimer's disease, Jan., 18
 - for dementia, Jan., 17-18
- Nitrofurantoin: causing pleural effusion, May, 319
- Nitroglycerin: causing platelet dysfunction, Aug., 613
- Nocardia infections: in AIDS, Oct., 745
- Nocturia: in elderly, Feb., 90
- Nootropics: in Alzheimer's disease, Jan., 49
- Nosocomial infections: in multiple organ failure syndrome, Dec., 878-880
- Novantrone: in malignant pleural effusions, May, 295
- Nuclear
 - cardiology (see Cardiology, nuclear)
 - magnetic resonance imaging (see Magnetic resonance imaging)
- Nursing home
 - incontinence in, urinary, Feb., 80
 - special care units for Alzheimer's patients, Jan., 36
- Nutritional support: in multiple organ failure syndrome, Dec., 882-883

O

- Obesity: upper body, related to glucose intolerance, hypertriglyceridemia, and hypertension, Nov., 790
- Oils: fish, and hypertension, Nov., 808
- Onion extracts: causing platelet dysfunction, Aug., 613
- Operating room: HIV transmission in, Sept., 666
- Opportunistic infections: in AIDS, treatment regimens, Oct., 724-725
- Oral
 - hairy leukoplakia in AIDS, Oct., 735
 - thrush in AIDS, Oct., 740
- Organ
 - multiple organ dysfunction syndrome (see Multiple organ dysfunction syndrome)
 - multiple organ failure syndrome (see Multiple organ failure syndrome)
- Orogenital transmission: of HIV, Sept., 659
- Orthopedic surgery: aspirin and platelet dysfunction, Aug., 611
- Ovarian
 - cancer, CA-125 in, Apr., 233
 - mesothelioma, Apr., 253-254
- Oxybutynin in geriatric urinary incontinence
 - mixed, Feb., 130
 - urge, Feb., 127
- Oxygen
 - consumption
 - demand in multiple organ failure syndrome, Dec., 863
 - during exercise, July, 567
 - flow-dependent, in multiple organ failure syndrome, Dec., 864
 - delivery, defective, causing polycythemia, Mar., 185-186
 - extraction failure in peripheral microcirculation in multiple organ failure syndrome, Dec., 865

transport in blood, July, 560-561
Oxyhemoglobin dissociation curve,
July, 560

P

P(A-a)O₂: abnormal, mechanisms
underlying, July, 556
Pads: absorbent, for geriatric uri-
nary incontinence, Feb., 120
Pain: chest, in cardiac evaluation,
June, 358-359
Palpation: cardiac, June, 368-369
Pancreas
cancer, CA 19-9 in, Apr., 234
disease differentiated from exu-
dative pleural effusions, May,
283
pleural effusion, chronic, May,
314
Pancreatitis
acute, pleural effusions in, May,
313
didanosine-induced, Oct., 713
Papillary stenosis: with sclerosing
cholangitis due to cytomega-
lovirus in AIDS, Oct., 731
Papillomavirus infection: in AIDS,
Sept., 671; Oct., 735-736
Papovavirus infection: in AIDS, Oct.,
736
Paragonimiasis: pleural, May, 310
Parapneumonic effusions and bac-
terial infections of pleural
space, May, 298-304
bacteriology, May, 299-300
chest tube drainage in
closed, May, 302-303
open, May, 304
clinical manifestations, May, 300
decortication in, May, 303-304
diagnosis, May, 300-301
loculated, May, 301
pathogenesis, May, 298
thrombolytic therapy in, May, 303
treatment, May, 301-304
Paromomycin: in cryptosporidiosis
in AIDS, Oct., 729
Parasitic infections: of pleural
space, May, 309-310

Paresthesias: in polycythemia vera,
Mar., 171
Parietal pleurectomy: in yellow nail
syndrome, May, 322
Parkinson's disease: dementia in,
Jan., 32-33
PCO₂: pleural fluid, in exudative
pleural effusions, May, 284
Pelvic
CT scans in unknown primary
malignancy, Apr., 228
inflammatory disease and AIDS,
Oct., 744-745
muscle exercises for geriatric in-
continence, Feb., 121
Penile clamp: for geriatric urinary
incontinence, Feb., 132-133
Pentamidine
aerosolized, in *Pneumocystis cari-
nii* disease in AIDS, Oct., 723
prophylactic, Oct., 726
parenteral, in *Pneumocystis cari-
nii* disease in AIDS, Oct., 722,
723
Peptic ulcer: and polycythemia
vera, Mar., 171
Perfusion
distribution, July, 557
imaging, myocardial (see Myocar-
dial, perfusion imaging)
tissue, in cardiac evaluation,
June, 380
venous-admixture-like, July, 557-
558
/ventilation mismatch, July, 557-
558
Pericardial
disease
cardiac catheterization in,
June, 483-487
echocardiography in, June,
454-455
MRI in, June, 464-465
pleural effusion due to, May,
321
on radiography, chest, June,
409-410
effusion
echocardiography in, June, 454,
455

- on radiography, chest, June, 409-410
- friction rub, June, 374, 377
- Pericardiocentesis: cardiac catheterization in cardiac tamponade after, June, 489
- Pericarditis, constrictive
 - cardiac catheterization in, June, 483-486
 - echocardiography in, June, 454-455
 - on radiography, chest, June, 410, 411
- Perinatal transmission of HIV, Sept., 662-663
- Peritoneal
 - dialysis and pleural effusions, May, 290
 - mesothelioma, Apr., 252-253
- Periurethral
 - abscess after chronic indwelling catheter, in elderly, Feb., 136
 - Teflon injections in geriatric urinary incontinence, Feb., 132
- Pessaries: in geriatric urinary incontinence, Feb., 133
- PET (*see* Tomography, positron emission)
- pH, pleural fluid, in pleural effusions
 - exudative, May, 284
 - malignant, May, 293
- Pharmacologic
 - manipulation in diagnosis of Huntington's disease, Jan., 34
 - restraint in Alzheimer's disease, Jan., 39
 - stress thallium imaging, June, 462-463
- Pharmacology
 - of didanosine, Oct., 711-712
 - of dideoxycytidine, Oct., 714
 - of zidovudine, Oct., 706-707
- Pheochromocytoma: and polycythemia, Mar., 186
- Phlebotomy: in polycythemia vera, Mar., 192-193
- Phosphorus: radioactive, in polycythemia vera, Mar., 195
- Physical activity
 - (*See also* Exercise)
 - hypertension and, Nov., 804-805
- examination
 - in cardiac evaluation, June, 362-380
 - in incontinence, geriatric urinary, Feb., 103, 106
 - in polycythemia vera, Mar., 173
- findings, abnormal, during exercise testing, June, 415
- Physicians: and Alzheimer's disease, Jan., 16
- Physiologic response: postresuscitative, Dec., 861-865
- Pick's disease, Jan., 33
- Pindolol: in Alzheimer's disease, Jan., 39
- Pipobroman: in polycythemia vera, Mar., 195
- Piracetam: in Alzheimer's disease, Jan., 49
- Plaques: neuritic, in Alzheimer's disease, Jan., 41-43
- Platelet
 - abnormalities in polycythemia vera, Mar., 172-173, 178-179
 - activating factor, Aug., 594
 - adhesions
 - disorders, Aug., 600-603
 - normal, Aug., 589-592
 - aggregation
 - disorders, Aug., 603-605
 - fibrinogen and, Aug., 596-597
 - glycoprotein IIb/IIIa complex and, Aug., 596-597
 - normal, Aug., 592-597
 - platelet agonists and, Aug., 592-594
 - signal transduction in, Aug., 594-596
 - tracings, Aug., 593
 - agonists and platelet aggregation, Aug., 592-594
 - alpha granules, Aug., 597-598
 - deficiency, Aug., 602, 606-607
 - dense granules, Aug., 598
 - deficiency, Aug., 607-608

Platelet (cont.)

- derived growth factor, Aug., 597
- factor 4, Aug., 597
- function
 - disorders (*see below*)
 - normal, Aug., 589-599
 - schematic illustrations, Aug., 590
- function disorders, Aug., 589-631
 - acquired (*see below*)
 - antifibrinolytic agents in, Aug., 622
 - congenital, Aug., 599-609
 - corticosteroids in, Aug., 621
 - DDAVP in, Aug., 620-621
 - estrogens in, conjugated, Aug., 621
 - management, Aug., 619-622
 - nontransfusion therapy for, Aug., 620-622
 - supportive care for, Aug., 619
 - transfusion for, Aug., 619-620
- function disorders, acquired, Aug., 609-619
- antibiotics causing, beta lactam, Aug., 612
- anticoagulants causing, Aug., 612-613
- antiplatelet antibodies and, Aug., 616-617
- antithrombotics causing, Aug., 612-613
- aspirin causing, Aug., 609-611
- cardiac bypass causing, Aug., 615-616
- drugs causing, Aug., 609-614
- drugs causing, nonsteroidal antiinflammatory, Aug., 611
- dysproteinemias causing, Aug., 617
- liver disease causing, Aug., 616
- medical conditions causing, Aug., 614-619
- myeloproliferative disorders causing, Aug., 617-618
- thrombolytics causing, Aug., 612-613
- uremia causing, Aug., 614-615
- gray platelet syndrome, Aug., 602, 606-607

- lysosomes, Aug., 598
- membrane protein deficiencies, Aug., 602-603
- Montreal platelet syndrome, Aug., 602
- procoagulant activity, Aug., 599
- disorders, Aug., 608-609
- secretion
 - disorders, Aug., 605-608
 - disorders due to abnormal secretory mechanism, Aug., 605-606
 - disorders due to platelet granule deficiency, alpha, Aug., 606-607
 - disorders due to platelet granule deficiency, dense, Aug., 607-608
 - normal, Aug., 597-598
 - signal transduction pathway in, Aug., 595
 - transfusion (*see* Transfusion, platelet)
- Plateletpheresis: in polycythemia vera, Mar., 190
- Platypnea: in cardiac evaluation, June, 358
- Plethora: in polycythemia vera, Mar., 173
- Plethysmograph: body, measurement of airway resistance in, July, 535
- Pleural
 - biopsy (*see* Biopsy, pleural)
 - diseases, May, 273-331
 - Churg-Strauss syndrome causing, May, 318
 - collagen vascular diseases causing, May, 317-319
 - immunoblastic lymphadenopathy causing, May, 319
 - Mediterranean fever causing, familial, May, 318-319
 - effusion (*see below*)
 - fluid
 - amylase in exudative pleural effusions, May, 282-283
 - antinuclear antibody measurement in lupus pleuritis, May, 318

- appearance in exudative pleural effusions, May, 281
- cytology (see Cytology, pleural fluid)
- diagnostic tests in exudative pleural effusions, May, 280-284
- formation, experimental studies, May, 276-277
- formation, physiology, May, 273-277
- glucose (see Glucose, pleural fluid)
- lactic dehydrogenase in exudative pleural effusions, May, 283
- lymphatic clearance, May, 275
- movement, pressures influencing, May, 274
- PCO₂ in exudative pleural effusions, May, 284
- pH (see pH, pleural fluid)
- white blood cell count and differential in exudative pleural effusions, May, 281-282
- mesothelioma (see Mesothelioma, pleural)
- space
- amebiasis, May, 309
 - aspergillosis in, May, 307
 - bacterial infections (see Parapneumonic effusions and bacterial infections of pleural space)
 - blastomycosis in, May, 307
 - coccidioidomycosis in, May, 307-308
 - cryptococcosis in, May, 308
 - echinococcosis, May, 310
 - fungal infections, May, 307-309
 - histoplasmosis in, May, 308-309
 - paragonimiasis, May, 310
 - parasitic infections, May, 309-310
- Pleural effusion
- after abdominal surgery, May, 316
 - after abscess, intra-abdominal, May, 315-316
 - in AIDS, May, 311
 - approach to patients with, May, 278-280
 - asbestos, May, 320
 - after bypass surgery, coronary artery, May, 321
 - diagnosis, differential, May, 278-279
 - dialysis and, peritoneal, May, 290
 - diaphragmatic hernia and, May, 316
 - drug reactions causing, May, 319
 - after esophageal perforation, May, 314-315
 - exudative, May, 292-298
 - bacteriologic stains in, May, 283
 - biopsy in, needle, May, 285-286
 - biopsy in, open, May, 287
 - bronchoscopy in, May, 286
 - criteria, May, 279
 - culture in, May, 283
 - diagnosis, differential, May, 280-285
 - immunologic studies in, May, 284
 - pleural fluid amylase in, May, 282-283
 - pleural fluid appearance in, May, 281
 - pleural fluid cytology in, May, 282
 - pleural fluid glucose in, May, 282
 - pleural fluid lactic dehydrogenase in, May, 283
 - pleural fluid pH and PCO₂ in, May, 284
 - pleural fluid white cell count and differential in, May, 281-282
 - pleuroscopy in, May, 286
 - undiagnosed, invasive tests for, May, 285-287
 - after Fontan procedure, May, 291
 - gastrointestinal tract diseases causing, May, 313-316
 - heart failure causing, congestive, May, 287-288
 - clinical manifestations, May, 287-288

- Pleural effusion (*cont.*)
 diagnosis, May, 288
 pathophysiology, May, 287
 treatment, May, 288
 in hepatic hydrothorax (*see* Hydrothorax, hepatic)
 incidence, annual, May, 280
 malignant, May, 292–296
 clinical manifestations, May, 292–293
 diagnosis, May, 293–294
 pathogenesis, May, 292
 treatment, May, 294–296
 in Meigs syndrome, May, 323–324
 miscellaneous causes, May, 320–324
 myxedema and, May, 291
 in nephrotic syndrome, May, 290
 pancreatic, chronic, May, 314
 in pancreatitis, acute, May, 313
 pericardial disease causing, May, 321
 in pneumonia, primary atypical, May, 311
 postcardiac injury syndrome causing, May, 320–321
 in pulmonary embolism, May, 312–313
 clinical manifestations, May, 312–313
 diagnosis, May, 313
 treatment, May, 313
 Q fever causing, May, 312
 in rickettsial infections, May, 311–312
 sarcoid, May, 322–323
 after sclerotherapy, endoscopic variceal, May, 316
 transudative, May, 287–291
 trapped lung causing, May, 323
 tuberculous, May, 304–306
 clinical manifestations, May, 305
 diagnosis, May, 306
 pathogenesis, May, 305
 treatment, May, 306
 uremic, May, 321–322
 in urinothorax, May, 291
 vena caval syndrome and, superior, May, 290–291
 in viral infections, May, 311–312
 in yellow nail syndrome, May, 322
 Pleurectomy: parietal, in yellow nail syndrome, May, 322
 Pleuritis
 lupus, May, 317–318
 rheumatoid, May, 317
 Pleurodesis in pleural effusion after Fontan procedure, May, 291
 malignant, May, 294, 295, 296
 in yellow nail syndrome, May, 322
 Pleuroperitoneal shunt (*see* Shunt, pleuroperitoneal)
 Pleuroscopy: in exudative pleural effusions, May, 286
Pneumocystis carinii disease: in AIDS, Oct., 721–726
 Pneumonia
 Pneumocystis carinii, in AIDS, Oct., 721–726
 primary atypical, pleural effusions in, May, 311
 Polycystic renal disease: and polycythemia, Mar., 186
 Polycythemia
 classification, Mar., 184
 relative, Mar., 183
 secondary, Mar., 184–185
 erythropoietin production increase causing, appropriate, Mar., 185–186
 erythropoietin production increase causing, inappropriate, Mar., 186
 hypoxemia causing, arterial, Mar., 185
 laboratory findings compared to findings in polycythemia vera, Mar., 188
 oxygen delivery defects causing, Mar., 185–186
 spurious, Mar., 183
 stress, Mar., 183
 vera, Mar., 165–212
 age and, Mar., 170
 alkylating agents in, Mar., 195
 bone marrow in, cytogenetics of, Mar., 182

- bone marrow in, location of, Mar., 179-181
- bone marrow in, morphology of, Mar., 181
- bone marrow in, MRI of, Mar., 181
- busulfan in, Mar., 196
- clinical course, Mar., 197-199
- clinical features, Mar., 170-173
- coagulation in, Mar., 178-179
- diagnosis, differential, Mar., 183-189
- diagnosis, Polycythemia Vera Study Group Criteria, Mar., 186-188
- erythroid colonies in, Mar., 168
- etiology, Mar., 165-170
- granulocytes in, Mar., 177-178
- hydroxyurea in, Mar., 193-195
- hydroxyurea in, red cell volume increase after, Mar., 176
- interferon in, Mar., 196
- laboratory findings in, Mar., 173-183
- laboratory findings in, comparison to findings in secondary polycythemia, Mar., 188
- laboratory findings in, miscellaneous, Mar., 182-183
- laboratory findings in, spurious, Mar., 183
- leukemia in, acute and chronic myeloid, Mar., 198
- leukocyte alkaline phosphatase in, Mar., 178
- management, acute, Mar., 189-191
- management, chronic, Mar., 191-197
- myeloid metaplasia after (see Myeloid, metaplasia, post-polycythemic)
- myelosuppressive therapy in, Mar., 193-196
- occult, and thrombocytosis, Mar., 175
- pathogenesis, Mar., 165-170
- phlebotomy in, Mar., 192-193
- phosphorus in, radioactive, Mar., 195
- physical examination in, Mar., 173
- platelet abnormalities in, Mar., 178-179
- platelet dysfunction in, Aug., 618
- progression from essential thrombocythemia, Mar., 190
- proliferative phase, Mar., 166-169
- spent phase, Mar., 169-170
- spent phase, clinical course, Mar., 198-199
- therapy, Mar., 189-197
- variant presentations, Mar., 189
- vitamin B₁₂ in, serum, Mar., 178
- Polymerase chain reaction: for HIV infection, Sept., 678-679
- Polyneuropathy: peripheral, in multiple organ failure syndrome, Dec., 886-887
- Positron emission tomography (see Tomography, positron emission)
- Postcardiac injury syndrome: pleural effusions in, May, 320-321
- Postresuscitative metabolism, Dec., 865-872
- Postresuscitative physiologic response, Dec., 861-865
- Potassium
 - intake increase in hypertension, Nov., 805-806
 - serum, in polycythemia vera, Mar., 183
- Power of attorney: and Alzheimer's disease, Jan., 37
- Pox virus infection: in AIDS, Oct., 736
- Praziquantel: in pleural paragonimiasis, May, 310
- Prednisolone: in tuberculous pleural effusions, May, 306
- Prednisone: in *Pneumocystis carinii* disease in AIDS, Oct., 722
- Pregnancy
 - aspirin and platelet dysfunction, Aug., 611

Pregnancy (cont.)

- induced hypertension and calcium supplements, Nov., 806
- polycythemia vera and, Mar., 197
- Prerenal azotemia: after resuscitation, Dec., 872
- Primaquine-clindamycin: in *Pneumocystis carinii* disease in AIDS, Oct., 722, 723
- Procabazine: causing pleural effusion, May, 319
- Propranolol
 - in Alzheimer's disease, Jan., 39
 - platelet dysfunction due to, Aug., 613
- Prostacyclin, Aug., 595-596
 - analogues in cardiac bypass surgery, Aug., 616
- Prostaglandin endoperoxide-induced platelet aggregation, Aug., 594
- Prostate
 - cancer (see Cancer, prostate)
 - enlargement and urinary flow rates, in elderly, Feb., 87
 - specific antigen (see Antigen, prostate-specific)
- Prostatitis: chronic, after chronic indwelling catheter, in elderly, Feb., 136
- Prostitutes: and HIV, Sept., 660
- Protein
 - amyloid precursor, in Alzheimer's disease, Jan., 43
 - catabolism, total body, after resuscitation, Dec., 871-872
 - induced storage pool deficiency, eosinophil, Aug., 619
 - platelet membrane, deficiencies, Aug., 602-603
- Prothrombin time: in polycythemia vera, Mar., 179
- Protozoan infections: in AIDS, Oct., 721-730
- Pruritus: in polycythemia vera, Mar., 171
- Pseudohypoparathyroidism: and dementia, Jan., 31

Psychological health: effect of geriatric urinary incontinence on, Feb., 82-83

Public health impact: of Alzheimer's disease, Jan., 13-16

Pulmonary

(See also Lung)

apoplexy, June, 361

embolism

acute, ECG in, June, 391

pleural effusion in (see Pleural effusion, in pulmonary embolism)

fibrosis, compliance in, July, 523
hypertension, chest pain in, June, 359

infarction causing hemoptysis in mitral stenosis, June, 361-362

involvement in multiple organ failure syndrome, Dec., 862-863

vascular disease and exercise, July, 570-571

gas exchange and, abnormal, July, 569

Pulmonic stenosis: on chest radiography, June, 406-407

Pulse

arterial

in cardiac evaluation, June, 366-368

wave configuration in cardiac evaluation, abnormal, June, 367-368

wave configuration in cardiac evaluation, normal, June, 366-367

bisferiens, June, 367

Corrigan's, June, 367

Pulsus

alternans, June, 367

paradoxus, June, 367-368

tardus, June, 367

Purpura, idiopathic thrombocytopenic

antiplatelet antibodies and, Aug., 617

Bernard-Soulier-like syndrome and, Aug., 602

P wave, June, 386

Pyelogram, IV

in hypertension, renovascular,
Nov., 821

in unknown primary malignancy,
Apr., 229

Pyelonephritis: after chronic in-
dwelling catheters, in elderly,
Feb., 136

Pyrimethamine

in isosporiasis in AIDS, Oct., 730

in toxoplasmosis in AIDS, Oct.,
727-728

Pyruvate production: after resusci-
tation, Dec., 867-869

Pyuria: in elderly men, Feb., 106

Q

Q fever: causing pleural effusions,
May, 312

QRS complex, June, 386-387

R

Radiation (see Irradiation)

Radioactive phosphorus: in polycy-
themia vera, Mar., 195

Radiography

chest

atrial enlargement on, June,
401-402, 403

cardiac appearance on, normal,
June, 398-399

cardiac appearance on, normal,
on frontal projection, June,
398-399

cardiac appearance on, normal,
on lateral projection, June,
399, 400

cardiac chamber enlargement
on, June, 399-402

in cardiac evaluation, June,
397-410

coarctation of aorta on, June,
407-409

in heart disease, congenital,
June, 405-409

in heart failure, congestive,
June, 402-405

in heart failure, congestive,
early, June, 403-404

pericardial disease on, June,
409-410

pericardial effusion on, June,
409-410

pericarditis on, constrictive,
June, 410, 411

in *Pneumocystis carinii* pneu-
monia in AIDS, Oct., 721-722

pulmonic stenosis on, June,
406-407

pulmonary edema on, June,
404-405

septal defect on, atrial, June,
406, 407

septal defect on, ventricular,
June, 406

ventricular enlargement on,
left, June, 401, 402

ventricular enlargement on,
right, June, 401

contrast agents causing platelet
dysfunction, Aug., 613

gastrointestinal, in unknown pri-
mary malignancy, Apr., 229

in incontinence, geriatric urinary,
Feb., 113

Radioimmunoprecipitation assays:
in HIV diagnosis, Sept., 675

Radiology

in Alzheimer's disease, Jan.,
23-26

functional imaging, Jan., 25-26

morphologic imaging, Jan.,
23-25

in malignancy of unknown origin,
Apr., 229

Radionuclide

angiocardigram, equilibrium,
June, 456-457

scans in unknown primary malig-
nancy, Apr., 229-230

Rectal electrical stimulator: in geri-
atric urinary incontinence,
Feb., 134

Red cell

mass

correlation between hematocrit
and, Mar., 174

Red cell (*cont.*)

- increased, and increased hematocrit, in differential diagnosis of polycythemia vera, Mar., 184-188
 - normal, and increased hematocrit, in differential diagnosis of polycythemia vera, Mar., 183-184
 - transfusion for anemia in post-polycythemic myeloid metaplasia, Mar., 201-202
 - volume increase after hydroxyurea in polycythemia vera, Mar., 176
- Reflexes: primitive, in Alzheimer's disease, Jan., 23
- Regurgitant valvular lesions: echocardiography in, June, 434-440
- Regurgitation
- aortic (*see* Aortic, regurgitation)
 - mitral (*see* Mitral, regurgitation)
 - tricuspid (*see* Tricuspid, regurgitation)
- Rehabilitation: after multiple organ failure syndrome, Dec., 886-887
- Relaxants: bladder, in geriatric urinary incontinence, Feb., 130
- Renal (*see* Kidney)
- Renin activity: plasma, and hypertension, Nov., 793-794
- Renovascular hypertension (*see* Hypertension, renovascular)
- Reperfusion injury: mediators of, Dec., 874
- Residual volume, July, 527
- Respiratory
- acid-base disturbances, July, 562-563
 - acidemia, July, 562
 - acidosis, July, 562
 - alkalemia, July, 563
 - alkalosis, July, 563
 - cardiorespiratory adaptation to exercise, July, 566-571
 - poor cooperation and, July, 571
 - distress syndrome, adult, platelet dysfunction in, Aug., 618-619
 - frequency increase, effect on dynamic lung compliance, July, 548
 - function evaluation in health and disease, July, 519-576
 - appendix, July, 573-576
 - muscle
 - endurance assessment, July, 552
 - fatigue, July, 553
 - function tests, July, 552
 - strength assessment, July, 552 - quotient during exercise, July, 570
 - rate
 - effect on alveolar ventilation, July, 554
 - during exercise, relation to tidal volume, July, 568 - response
 - to carbon dioxide, July, 564-565
 - to hypoxemia, July, 565
- Respite care: in Alzheimer's disease, Jan., 35-36
- Restraint: pharmacologic, in Alzheimer's disease, Jan., 39
- Resuscitation
- metabolism after, Dec., 865-872
 - physiologic response after, Dec., 861-865
- Reticulin: in polycythemia vera, Mar., 181
- Reverse transcriptase inhibitors: in AIDS, Oct., 715-716
- Rheumatoid pleuritis, May, 317
- Rib notching: on chest radiograph in coarctation of aorta, June, 408-409
- Ribonucleic acid: in multiple organ failure syndrome therapy, Dec., 885
- Rickettsial infections: causing pleural effusions, May, 311-312
- Rifampin: in tuberculous pleural effusions, May, 306
- Ristocetin: and platelet adhesion, Aug., 591-592
- Rod: Harrington, for spinal fusion, and DDAVP, Aug., 621

- Romhilt-Estes ECG point system:
for left ventricular hypertro-
phy, June, 389
Rub: pericardial friction, June, 374,
377
Ruddy cyanosis: in polycythemia
vera, Mar., 173

S

- Salmonella* infections: in AIDS, Oct.,
744
Sarcoidosis
biopsy in, endomyocardial, June,
488
pleural effusion due to, May,
322-323
Sarcoma
Kaposi's, in AIDS, Oct., 746-748
pleural effusions and, May,
311
soft-tissue, cytogenetic analysis,
Apr., 241
Scan (see Imaging)
Sclerosing cholangitis: with papil-
lary stenosis due to cytomeg-
alovirus in AIDS, Oct., 731
Sclerotherapy: endoscopic variceal,
pleural effusions after, May,
316
Sedating neuroleptics: for sleep/
wake disturbances in Alzhei-
mer's disease, Jan., 38
Seizures
didanosine-induced, Oct., 713
zidovudine overdosage causing,
Oct., 710
Septal defect
atrial
echocardiography in, June,
453-454
echocardiography in, transe-
sophageal, June, 428
on radiography, chest, June,
406, 407
ventricular
echocardiography in, June,
453-454
on radiography, chest, June,
406
Serotonin-induced platelet aggrega-
tion, Aug., 594
Sexual transmission: of HIV, Sept.,
659-661
Sexually transmitted diseases: and
HIV transmission, Sept., 661
Shigella infections: in AIDS, Oct.,
745
Shingles: and HIV infection, Sept.,
671
Shock
heat shock genes in multiple or-
gan failure syndrome, Dec.,
878
warm, June, 380
Shunt
pleuroperitoneal, for pleural effu-
sions
after Fontan procedure, May,
291
in heart failure, congestive,
May, 288
malignant, May, 295-296
in yellow nail syndrome, May,
322
right-to-left, and polycythemia,
Mar., 185
true, July, 558-559
Single photon emission tomography
(see Tomography, single pho-
ton emission)
SIRS (see Systemic inflammatory
response syndrome)
Skin
problems due to geriatric urinary
incontinence, Feb., 82
testing, tuberculin, in AIDS, Oct.,
739
Sleep
apnea and drug therapy in hy-
pertension, Nov., 824-825
disturbances in Alzheimer's dis-
ease, management, Jan., 38
Sling procedure: for stress urinary
incontinence, in elderly, Feb.,
131
Smoking
Alzheimer's disease and, Jan., 15
cessation and hypertension, Nov.,
795, 798-799

Smoking (*cont.*)

- hypercholesterolemia and, Nov., 789
- neuroendocrine carcinoma and, poorly differentiated, in men, Apr., 252
- polycythemia due to, Mar., 186
- Social well-being: effect of geriatric urinary incontinence on, Feb., 82-83
- Sodium restriction: in hypertension, Nov., 800-803
- Soft-tissue sarcoma: cytogenetic analysis, Apr., 241
- Sokolow-Lyons ECG criteria: for left ventricular hypertrophy, June, 389
- Solid tumors: chromosomal abnormalities in, Apr., 242
- Somatostatin
 - in Alzheimer's disease, Jan., 46-47
 - analogues in cryptosporidiosis in AIDS, Oct., 729
- Sound(s)
 - breath, June, 378-379
 - heart
 - first, June, 369-372
 - fourth, June, 372
 - second, June, 369-372
 - second, causes of exaggerated or reversed splitting of, June, 371
 - third, June, 372
 - wave imaging, principles, June, 417-419
- SPECT (*see* Tomography, single photon emission)
- Speech disturbances: in parkinsonian dementia, Jan., 33
- Sphincters: artificial, in geriatric urinary incontinence, Feb., 133
- Spinal fusion: Harrington rod, DDAVP in, Aug., 621
- Spiramycin in AIDS
 - for cryptosporidiosis, Oct., 729
 - for toxoplasmosis, Oct., 728
- Spirometry: prediction equations for, July, 574

Spleen

- enlargement
 - in myeloid metaplasia, post-polycythemic, therapy, Mar., 203-204
 - in polycythemia vera, Mar., 173
- irradiation in postpolycythemic myeloid metaplasia, Mar., 204
- Splenectomy in postpolycythemic myeloid metaplasia, Mar., 203
- leukemia after, acute, Mar., 201
- Spongiform encephalopathy, Jan., 34
- Squamous cell carcinoma: of unknown primary origin, Apr., 249
- Squatting: cardiac auscultation during, June, 377
- Stains
 - bacteriologic, in exudative pleural effusions, May, 283
 - immunocytochemical (*see* Immunocytochemistry)
- Stanford biptome: in endomyocardial biopsy, June, 488-489
- Staphylococcus aureus* infections: in AIDS, Oct., 744
- Stenosis
 - aortic
 - cardiac catheterization in, June, 473-476
 - echocardiography in, June, 433-434
 - mitral
 - cardiac catheterization in, June, 470-473
 - echocardiography in, June, 431-433
 - hemoptysis due to, June, 361-362
 - papillary, with sclerosing cholangitis due to cytomegalovirus in AIDS, Oct., 731
 - pulmonic, on chest radiography, June, 406-407
 - tricuspid, cardiac catheterization in, June, 473
- Stenotic lesions: echocardiography in, June, 431-434

Steroids

(See also Corticosteroids)

anabolic, for anemia in postpolycythemic myeloid metaplasia, Mar., 202

Stones: urinary, after chronic indwelling catheter, in elderly, Feb., 136

Streptococcus pneumoniae infections: in AIDS, Oct., 744

Streptokinase: in parapneumonic effusions, May, 303

Stress

echocardiography, June, 450-451

incontinence (see Incontinence, urinary, geriatric, stress)

management in hypertension, Nov., 806-808

pharmacologic, for thallium imaging, June, 462-463

polycythemia, Mar., 183

Stroke

bilateral, and dementia, Jan., 29

effect of drug therapy in hypertension on, Nov., 811

potassium intake and, Nov., 805

Strongyloidiasis: disseminated, in AIDS, Oct., 730

ST segment (see Electrocardiography, exercise, ST segment on)

Subdiaphragmatic unknown primary malignancy: pathologic evaluation, Apr., 244

Sulfa: triple, in toxoplasmosis in AIDS, Oct., 727-728

Sulfadiazine: in toxoplasmosis in AIDS, Oct., 727-728

Supportive care: for platelet function disorders, Aug., 619

Supradiaphragmatic unknown primary malignancy: pathologic evaluation, Apr., 243-244

Surface markers: in unknown primary malignancy, Apr., 243

Surgery: abdominal, pleural effusion after, May, 316

Sweating: in polycythemia vera, Mar., 171

Syncope: in cardiac evaluation, June, 359-360

Syphilis: and AIDS, Oct., 745

Systemic inflammatory response syndrome

(See also Multiple organ failure syndrome)

discussion of term, Dec., 857

Systolic function, echocardiography of (see Echocardiography, of systolic function)

T

Tachycardia: multifocal atrial, in cor pulmonale, June, 392

Talc: in malignant pleural effusions, May, 295

Tamponade, cardiac

cardiac catheterization in, June, 486-487, 488, 489

echocardiography in, June, 454

T cell(s)

in AIDS, Sept., 652-654

lymphotropic virus-I/II infection, human, in AIDS, Oct., 736

Technetium-99m MIBI myocardial perfusion imaging, June, 463

Teflon injections: periurethral, in geriatric urinary incontinence, Feb., 132

Terodiline: in geriatric urinary incontinence, Feb., 127-130

Tetracycline: in malignant pleural effusions, May, 294-295

Tetrahydroaminoacridine: in Alzheimer's disease, Jan., 48

Tetrahydroimidazobenzodiazepine compounds: in AIDS, Oct., 715-716

Thalamic involvement: in dementia, Jan., 29

Thallium imaging, June, 460-463

exercise, June, 461-462
pharmacological stress, June, 462-463

Theophylline toxicity: causing multifocal atrial tachycardia, June, 392

- Thioridazine: in Alzheimer's disease, Jan., 38
- Thoracoscopy: in malignant mesothelioma diagnosis, May, 297
- Thrills, June, 369
- Thrombasthenia: Glanzmann, Aug., 603-605
- Thrombi
- atrial, echocardiography in, June, 452-453
 - transesophageal, June, 427-428
 - ventricular, echocardiography in, June, 452-453
- Thrombin: platelet receptor for, Aug., 592
- Thrombocythemia, essential
- age and, Mar., 170
 - progression to polycythemia vera, Mar., 190
- Thrombocytopenia
- HIV-associated, zidovudine in, Oct., 709
 - in postpolycythemia myeloid metaplasia, therapy, Mar., 203
- Thrombocytopenic purpura (*see* Purpura, idiopathic thrombocytopenic)
- Thrombocytosis: and occult polycythemia vera, Mar., 175
- β -Thromboglobulin, Aug., 597
- Thrombolytics
- in parapneumonic effusions, May, 303
 - platelet dysfunction due to, Aug., 612-613
- Thrombosis: hepatic vein, and polycythemia vera, Mar., 171
- Thrombospondin, Aug., 597-598
- Thrombotic complications: in polycythemia vera, Mar., 171-172
- Thrush: oral, in AIDS, Oct., 740
- Thyroid scans: in unknown primary malignancy, Apr., 229-230
- TIBO compounds: in AIDS, Oct., 715-716
- Ticlopidine: effect on platelet function, Aug., 613
- Tidal volume
- effect on alveolar ventilation, July, 554
 - related to respiratory rate during exercise, July, 568
- Tissue perfusion: in cardiac evaluation, June, 380
- Toilet substitutes: in geriatric urinary incontinence, Feb., 119
- Toileting: scheduled, for geriatric urinary incontinence, Feb., 124
- Tomography
- computed
 - in Alzheimer's disease, Jan., 25
 - differentiating lung abscess from empyema, May, 301
 - in malignancy of unknown primary origin, Apr., 228-229
 - in mesothelioma, malignant, May, 296
 - in Pick's disease, Jan., 33
 - positron emission
 - in Alzheimer's disease, Jan., 25
 - in dementia, hydrocephalic, symptomatic, Jan., 30
 - in dementia, vascular, Jan., 30
 - in Huntington's disease, Jan., 34
 - in Pick's disease, Jan., 33
 - single photon emission
 - in Alzheimer's disease, Jan., 25-26
 - in dementia, vascular, Jan., 30
 - in Pick's disease, Jan., 33
- Total lung capacity: subdivisions of lung volume as proportion of, July, 526
- Toxicity
- cardiotoxicity, doxorubicin, endomyocardial biopsy in, June, 488
 - didanosine, Oct., 713
 - dideoxycytidine, Oct., 715
 - drug, causing dementia, Jan., 27-28
 - foscarnet, Oct., 732-733
 - theophylline, causing multifocal atrial tachycardia, June, 392
 - zidovudine, Oct., 709-710

- Toxoplasmosis: in AIDS, Oct., 726-728
- Tranexamic acid: for platelet function disorders, Aug., 622
- Transcobalamins: in polycythemia vera, Mar., 177-178
- Transcriptase inhibitors: reverse, in AIDS, Oct., 715-716
- Transesophageal echocardiography, June, 425-428
- Transfusion
-associated HIV, Sept., 663-664
platelet
 in cardiac bypass surgery, Aug., 616
 in platelet function disorders, Aug., 619-620
 red cell, for anemia in postpolycythemic myeloid metaplasia, Mar., 201-202
- Transplacental transmission: of HIV, Sept., 663
- Transplantation
 bone marrow, in Glanzmann's thrombasthenia, in children, Aug., 605
 HIV transmission by, Sept., 664
- Trapped lung: causing pleural effusion, May, 323
- Trauma: head, as risk factor in Alzheimer's disease, Jan., 15
- Trazodone: in Alzheimer's disease, Jan., 39
- Treadmill testing: post myocardial infarction, June, 416
- Tricuspid
 regurgitation
 cardiac catheterization in, June, 481
 echocardiography in, June, 437-440
 stenosis, cardiac catheterization in, June, 473
- Trifluridine: topical, in herpes simplex virus infection in AIDS, Oct., 734
- Triglycerides: pleural fluid, in exudative pleural effusions, May, 284
- Trimethoprim
 -dapsone in *Pneumocystis carinii* disease in AIDS, Oct., 722, 723
 -sulfamethoxazole
 in isosporiasis in AIDS, Oct., 730
 in *Pneumocystis carinii* disease in AIDS, Oct., 722, 723
 prophylactic, in *Pneumocystis carinii* disease in AIDS, Oct., 726
- Trimetrexate: in *Pneumocystis carinii* disease in AIDS, Oct., 723
- Tube(s) (see Chest, tubes)
- Tuberculin skin testing: in AIDS, Oct., 739
- Tuberculous pleural effusion (see Pleural effusion, tuberculous)
- Tumor
 germ cell (see Germ cell tumor)
 heart (see Heart, tumors)
 -host interactions during metastatic cascade, Apr., 224
 kidney, and polycythemia, Mar., 186
 markers in unknown primary malignancy, Apr., 230-234
 solid, chromosomal abnormalities in, Apr., 242
- T wave, June, 387
- Twin studies: in Alzheimer's disease, Jan., 26
- U
- Ubiquitin: in neurofibrillary tangles in Alzheimer's disease, Jan., 44
- Ulcer
 esophageal, zidovudine-induced, Oct., 710
 peptic, and polycythemia vera, Mar., 171
- Ultrasound: for residual urine measurement in geriatric incontinence, Feb., 110
- Unknown primary malignancy, Apr., 221-260
 biologic principles, Apr., 245-246

Unknown primary malignancy (*cont.*)

- CT in, Apr., 228-229
 - cytogenetic analysis, Apr., 241-242
 - detection, Apr., 222-223
 - diagnosis, Apr., 227-244
 - flow schema for, Apr., 247
 - summary, Apr., 246
 - diagnostic studies, Apr., 228-230
 - molecular, Apr., 243
 - DNA probes in, Apr., 243
 - evaluation, Apr., 227-244
 - hormonal receptors in, Apr., 241
 - imaging in, Apr., 229
 - immunocytochemistry in, Apr., 235-240
 - screening panel of, Apr., 238-239
 - incidence, Apr., 222-223
 - individual syndromes, Apr., 249-254
 - metastatic involvement in, Apr., 223
 - microscopy in
 - electron, Apr., 240-241
 - light, Apr., 235
 - MRI, in, Apr., 230
 - pathologic evaluation, Apr., 234-244
 - based on anatomic distribution, Apr., 243-244
 - radiology in, Apr., 229
 - radionuclide scans in, Apr., 229-230
 - subdiaphragmatic, pathologic evaluation, Apr., 244
 - summary, Apr., 254-255
 - supradiaphragmatic, pathologic evaluation, Apr., 243-244
 - surface markers in, Apr., 243
 - survival after, Apr., 227
 - treatment, Apr., 246-249
 - flow schema for, Apr., 247
 - tumor markers in, Apr., 230-234
- Unknown primary origin
- adenocarcinoma of, Apr., 252, 254
 - chemotherapy, Apr., 248
 - carcinoma of
 - neuroendocrine, poorly differentiated, Apr., 251-252
 - squamous cell, Apr., 249

germ cell tumors of (*see* Germ cell tumor)

lymphoma of, large-cell, Apr., 250-251

malignancy of (*see* Unknown primary malignancy *above*)

mesothelioma of

- ovarian, Apr., 253-254
- peritoneal, Apr., 252-253

Uracil

in multiple organ failure syndrome, Dec., 885

mustard in polycythemia vera, Mar., 195

Ureagenesis: after resuscitation, Dec., 872

Uremia

platelet dysfunction in, Aug., 614-615

pleural effusion due to, May, 321-322

Urethra

(*See also* Periurethral)

pressure

age and, in women, Feb., 87

profile in geriatric urinary incontinence, Feb., 116-117

Uric acid: in polycythemia vera, Mar., 182

Urinary

continence (*see* Continence, urinary)

incontinence (*see* Incontinence, urinary)

sphincters, artificial, in geriatric incontinence, Feb., 133

stones after chronic indwelling catheter, in elderly, Feb., 136

tract

infections due to catheters, chronic indwelling, in elderly, Feb., 136

infections due to incontinence, in elderly, Feb., 82

lower, abnormalities underlying incontinence, Feb., 93

lower, innervation of, basic, Feb., 85

lower, normal pressure volume relationships in, Feb., 86

lower, pathology, after chronic indwelling catheter, in elderly, Feb., 136

Urination

age-related changes in, Feb., 87-92

normal, Feb., 83-87
anatomic components, Feb., 84

Urine

residual, measurement in geriatric incontinence, Feb., 110
specimen in diagnostic evaluation of geriatric incontinence, Feb., 106

Urothorax, May, 291

Urodynamic testing in geriatric urinary incontinence
complex, Feb., 113, 116-117
simple, Feb., 111

Uroflowmetry: in geriatric urinary incontinence, Feb., 116

Urokinase: in parapneumonic effusions, May, 303

Uterine myomas: and polycythemia, Mar., 186

V

Vaccines: in AIDS, Oct., 720

Vaccinia virus infection: in AIDS, Oct., 736

Vaginitis: *Candida*, in AIDS, Oct., 740, 741

Valsalva: cardiac auscultation during, June, 377

Valve

aortic (see Aortic)
mitral (see Mitral)
tricuspid (see Tricuspid)

Valvular

heart disease (see Heart, disease, valvular)

lesions, regurgitant, echocardiography in, June, 434-440

Variceal sclerotherapy: endoscopic, pleural effusions after, May, 316

Varicella-zoster virus infection: in AIDS, Oct., 734-735

Varices: bronchial, causing hemoptysis in mitral stenosis, June, 361

Vascular

cardiovascular (see Cardiovascular)

cerebrovascular amyloid in Alzheimer's disease, Jan., 43

dementia, Jan., 29-30
disease

collagen, causing pleural disease, May, 317-319

pulmonary, and exercise, July, 570-571

pulmonary, and exercise, abnormal gas exchange during, July, 569

resistance, systemic, in multiple organ failure syndrome, Dec., 864

Vasculitis: and dementia, Jan., 32

Vasopressin-induced platelet aggregation, Aug., 594

Vein

(See also Venous)

bronchial, varices, causing hemoptysis in mitral stenosis, June, 361

hepatic, thrombosis, and polycythemia vera, Mar., 171

Vena caval syndrome: superior, and pleural effusions, May, 290-291

Venous

(See also Vein)

admixture

-like perfusion, July, 557-558

true, July, 558-559

pressure(s)

in cardiac evaluation, June, 362-365

wave configuration in cardiac evaluation, abnormalities, June, 364-365

wave configuration in cardiac evaluation, normal, June, 362-364

Ventilation

alveolar, July, 553-555

dead-space-like, July, 558

- Ventilation (*cont.*)
 distribution, July, 555-556
 in upright lung, July, 556
 maximum voluntary, July, 538
 /perfusion mismatch, July, 557-558
- Ventilatory
 abnormality, patterns of, July,
 538-553
 function
 disturbances in obstructive and
 restrictive disease, July, 538
 tests, July, 521-538
 limitation during exercise, July,
 566-568
 pattern
 obstructive, July, 539, 540-541
 obstructive, post-
 bronchodilator studies, July,
 540, 541, 542
 restrictive, July, 538-539
- Ventricle
 contraction beats, premature,
 auscultation after, June, 378
- left
 dilatation, echocardiography,
 June, 447
 enlargement, on chest radiog-
 raphy, June, 401, 402
 hypertrophy (*see* Hypertrophy,
 ventricular, left)
 impulse, apical, June, 368
 systolic function, echocardiog-
 raphy of (*see* Echocardiog-
 raphy, of systolic function, left
 ventricular)
- right
 dilatation, echocardiography,
 June, 447-448
 enlargement, on chest radiog-
 raphy, June, 401
 function evaluation by first-
 pass radionuclide studies,
 June, 458-459
 hypertrophy (*see* Hypertrophy,
 ventricular, right)
 impulse, June, 369
 systolic function, echocardiog-
 raphy, June, 445-446
 septal defect (*see* Septal defect,
 ventricular)
- thrombi, echocardiography in,
 June, 452-453
- Ventriculography, left, June,
 467
 interpretation, June, 468-469
- Verapamil: in multifocal atrial
 tachycardia, June, 392
- Vessel (*see* Vascular)
- Vidarabine: in herpes simplex infec-
 tion in AIDS, Oct., 734
- Virus
 adenovirus infection in AIDS,
 Oct., 736
 culture in HIV diagnosis, Sept.,
 677-678
 cytomegalovirus infection in
 AIDS, Oct., 730-733
 Epstein-Barr virus infection in
 AIDS, Oct., 735
 herpes (*see* Herpes)
 immunodeficiency, human (*see*
 HIV)
 infections
 in AIDS, Oct., 730-736
 pleural effusion due to, May,
 311-312
 lymphotrophic, HTLV-I/II infec-
 tion in AIDS, Oct., 736
 papillomavirus infection in AIDS,
 Sept., 671; Oct., 735-736
 papovavirus infection in AIDS,
 Oct., 736
 pox virus infection in AIDS, Oct.,
 736
 vaccinia virus infection in AIDS,
 Oct., 736
 varicella-zoster virus infection in
 AIDS, Oct., 734-735
- Visual abnormalities: in polycythe-
 mia vera, Mar., 171
- Vital capacity, July, 531
 forced (*see* Forced vital capacity)
- Vitamin B₁₂: serum, in polycythemia
 vera, Mar., 177-178
- Voiding
 difficulty, in elderly, Feb., 90
 prompted, for geriatric urinary
 incontinence, Feb., 125-
 127
- von Willebrand factor, Aug., 591

W

- Wake disturbances: in Alzheimer's disease, management, Jan., 38
- Warm shock, June, 380
- Wave
 - P, June, 386
 - sound wave imaging, principles, June, 417-419
 - T, June, 387
- Weakness: in polycythemia vera, Mar., 171
- Weight
 - loss in polycythemia vera, Mar., 171
 - reduction in hypertension, Nov., 799-800
- Well-being: social, effect of geriatric urinary incontinence on, Feb., 82-83
- Western blot: in HIV diagnosis, Sept., 673-675
- White blood cell (*see* Leukocyte)
- Winter bronchitis: causing hemoptysis in mitral stenosis, June, 362

Workers: health care, HIV transmission to, Sept., 665-667

Y

- Yellow nail syndrome: causing pleural effusion, May, 322

Z

- Zidovudine in AIDS, Oct., 706-711
 - acyclovir combined with, Oct., 716
 - clinical use, Oct., 707-709
 - interferon alpha combined with, Oct., 716
 - leukoplakia regression after, oral hairy, Oct., 735
 - mechanism of action, Oct., 706
 - pharmacology, Oct., 706-707
 - resistance, Oct., 710-711
 - toxicity, Oct., 709-710
- Zoster virus infection: in AIDS, Sept., 671; Oct., 734-735